University of Kentucky

UKnowledge
Theses and Dissertations--Veterinary Science

Veterinary Science

2013

EVIDENCE FOR THE MATURATION OF CELLULAR IMMUNE
RESPONSES IN EQUINE INFECTIOUS ANEMIA VIRUS-INFECTED
PONIES
Chong Liu
University of Kentucky, liuc568@gmail.com

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Liu, Chong, "EVIDENCE FOR THE MATURATION OF CELLULAR IMMUNE RESPONSES IN EQUINE
INFECTIOUS ANEMIA VIRUS-INFECTED PONIES" (2013). Theses and Dissertations--Veterinary Science.
10.
https://uknowledge.uky.edu/gluck_etds/10

This Doctoral Dissertation is brought to you for free and open access by the Veterinary Science at UKnowledge. It
has been accepted for inclusion in Theses and Dissertations--Veterinary Science by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained and attached hereto needed written
permission statements(s) from the owner(s) of each third-party copyrighted matter to be
included in my work, allowing electronic distribution (if such use is not permitted by the fair use
doctrine).
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive
and make accessible my work in whole or in part in all forms of media, now or hereafter known.
I agree that the document mentioned above may be made available immediately for worldwide
access unless a preapproved embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s dissertation
including all changes required by the advisory committee. The undersigned agree to abide by
the statements above.
Chong Liu, Student
Dr. David W. Horohov, Major Professor
Dr. Daniel K. Howe, Director of Graduate Studies

EVIDENCE FOR THE MATURATION OF CELLULAR IMMUNE RESPONSES IN
EQUINE INFECTIOUS ANEMIA VIRUS-INFECTED PONIES

DISSERTATION

A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
College of Agriculture
at the University of Kentucky

By
Chong Liu
Lexington, Kentucky
Director: Dr. David W. Horohov, Professor of Immunology
Lexington, Kentucky
2013

Copyright © Chong Liu 2013

ABSTRACT OF DISSERATION

EVIDENCE FOR THE MATURATION OF CELLULAR IMMUNE RESPONSES IN
EQUINE INFECTIOUS ANEMIA VIRUS-INFECTED PONIES

Equine infectious anemia virus (EIAV) has been used as a model to investigate
protective mechanisms against lentiviruses. Unlike other lentiviruses, EIAV replication can be
eventually controlled in most infected horses leading to an inapparent carrier state free of overt
clinical signs which can last for many years. Maintenance of this carrier state is absolutely
dependent on active immune responses as evidenced by the fact that immunosuppressive drugs
can induce the recurrence of disease. However, the immune mechanisms that are responsible
for this control of infection are not yet identified. As the resolution of the initial infection is
correlated with the appearance of the virus-specific cytotoxic T lymphocytes (CTL), it appears
that cellular immune responses play an important role. However, most studies into this
protective mechanism have been limited to the identification of specific epitopes, usually at a
single time point in the infection. Few studies have examined the cellular immune responses
to the viral antigens throughout the infection period. Since the virus undergoes rapid mutation
following infection, the adaptive immune response must also evolve to meet this challenge.
Previously, the EIAV envelope (gp90) protein was shown to be the primary determinant of
vaccine efficacy. Here, we hypothesized that the maturation of cellular immune responses is a
lengthy process and involves envelope-specific T cell recognition shifting from
immunodominant variable determinants to conserved immunorecessive determinants during the
initial stages of the EIAV infection. The first part of this dissertation was to develop a new in
vivo method to identify envelope-specific T cell responses. The second part of this dissertation
was to investigate whether envelope-specific T cell recognition evolved in EIAV-infected
ponies. Finally, the mechanisms for this T cell immunodominant shifting were also investigated
from the point of both virus sequence mutation and T cell clone expansion and contraction.
Also, a new EIAV attenuated vaccine which contained a consensus gp90 sequence was tested
to see if it facilitated T cell recognition of the more conserved regions early in the infection.
Our results indicated that envelope-specific T cell recognition patterns changed over time.
Early after infection, dominant immune responses to the peptides in the carboxyl-terminus
variable region were identified. By six months post infection, the recognized peptides spanned
the entire envelope sequence, with a shift to the amino-terminus conserved region. The
mechanisms responsible for this change remain unclear, but analysis of T cell receptor
repertoire indicated that T cell clonal expansion and contraction might be one of the reasons.
Our demonstration that envelope-specific peptide recognition shifts from the variable to the
more conserved regions provides evidence that the maturation of cell mediated immune
response is parallelled with long-term control of this infection.

Keywords: Equine infectious anemia virus, Cellular immune responses, immunodominant
recognition, immunodominant shifting, consensus sequence

Chong Liu
June,11,2013

THE MATURATION OF CELLULAR IMMUNE RESPONSES IN EQUINE
INFECTIOUS ANEMIA VIRUS-INFECTED HORSES
BY
Chong Liu

David W. Horohov
Director of Dissertation
Daniel Howe
Director of Graduate Studies
July 28, 2013

Dedication
This doctoral dissertation is dedicated to my beloved family members:
Father: Decai Liu
Mother: Wenxia Ni
Husband: Jinpeng Liu

ACKNOWLEDGEMENTS
There are so many people who have given me support for my growth both
professionally and personally during my graduate study. It is a pleasure to convey my
gratitude towards the following people
First of all, I would like to thank my mentor Dr. Horohov. He has provided me with
tremendously help and support the entire time. With his support and quick wit, I am able
to grow from a student to a scientific researcher. Facing tons of failures in pursuing to my
research goal, he never put any negative attitude towards me. Instead, he always shows his
support and helps me figure out the right directions. Thanks for your endless understanding
and granting me the freedom to make mistakes, and learn from them. Also, I would like to
thank all members in Dr. Horohov lab. Dr. Amanda, Dr. Allen, Macarena Sanz, Melissa
Siard, Nick, Alex, Craig, and Talia. Thank you all for your generous help through these
years. It is a great honor to work with all of you.
Also, I would like to thank members of my dissertation committee, Dr. Charles
Issel, Dr. Frank Cook, Dr. Thomas Chambers, Dr. Don Cohen, and the outside examiner
Dr. Jiayou Zhang for their time and dedication. Their suggestions and insight have been
invaluable to this dissertation. Dr. Cohen has provided me with tremendous help about
setting cytototoxic assays. Without his help, these projects would not have been completed.
Then, I would like to thank all members in EIAV group. Thanks Dr. Issel, Dr. Cook,
Dr. Montelaro (University of Pittsburgh) and Dr. Craigo (University of Pittsburgh) for
providing me incredible knowledge in EIAV research, and generous resources of studying
this virus. Especially, Sheila Cook, who helps me so much in EIAV research. Working
with her has provided me tremendous experience in the field and will be valuable for my
iii

future as well. Zach Willand and Keiko Moore also help me a lot during the EIAV study
on the farm. Thank them for their time and handling ponies.
I would like to extend my appreciation to all the members in the Gluck Equine
Research Center. Particularly, I would like to thank Dr. Troedsson, Dr. Chambers, Dr. Issel,
Dr. Cook, Dr. Balasuriya, and Dr. MacLeod for allowing me using their equipment. I would
like to thank Dr. Loynachan for the support in immunohistochemistry staining. I would
like to thank Dr. Daniel Howe for his support as the Director of Graduate Studies. Also, I
would also like to thank all the administrative staff in the Gluck Equine Reseach Center,
especially Roy Leach, Debbie Mollet, Gail Watkins, Patsy Garrett and Doris, who are
always ready to help me. I would like to thank all the staffs at the farm for their tireless
efforts to take care of the horses and ponies. Additionally, I would like to thank all graduate
students in Gluck Equine Research Center. We have become a family away from family,
helping one another through the challenges. Especially, I would like to thank Wenying
Zhu, Elizabeth Woodward, Rafaela de Negri, Ablesh Gautam, Ashish Tiwari and Sanjay
Sarkar, who have being wonderful friends.
Last but not least, I would like to extend a thank you to my amazing family
members, who have been the major driving force throughout my academic career. Without
their understanding and support, the path I chose would not have been possible.

iv

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ............................................................................................... iii
List of Tables ................................................................................................................... viii
List of Figures .................................................................................................................... ix
CHAPTER 1 Review of the Literature ............................................................................. 10
1.1 EIAV is a model for lentivirus protection............................................................... 10
1.1.1 EIAV structure ..................................................................................................10
1.1.2 Clinical course of EIAV infection ....................................................................12
1.2 Host defense mechanisms to viral infections .......................................................... 14
1.2.1 Innate immune response against viral infection................................................14
1.2.2 Adaptive immune responses against viral infection .........................................17
1.3 Immune responses associated with lentiviral infection .......................................... 20
1.3.1 Humoral Immune Responses ............................................................................20
1.3.2 Cellular mediated immunity (CMI) ..................................................................21
1.3.3 Antigen sensitivity and TCR avidity.................................................................23
1.4 Questions regarding assays to measure CMI responses in lentivirus systems........ 25
1.5 Immunodominance and immunodominance shifting.............................................. 27
1.5.1 Immunodominance and the mechanisms of immunodominant shifting ...........27
1.5.2 Immunodominance and immunodominant shifting in lentivirus infection.......29
1.6 Host immune response to EIAV infection .............................................................. 30
1.6.1 Humoral immune responses against EIAV infection........................................30
1.6.2 Cellular mediated immunity (CMI) against EIAV infection ............................31
CHAPTER 2 Hypothesis and specific aims...................................................................... 33
CHAPTER 3 The determination of in vivo envelope-specific cell-mediated immune
responses in Equine Infectious Anemia Virus-infected ponies......................................... 36
3.1 Summary ................................................................................................................. 37
3.2 Introduction ............................................................................................................. 39
3.3 Materials and method.............................................................................................. 40
3.3.1 Animals, virus and experimental challenges ....................................................40
3.3.2 Production of synthetic peptides and construction of peptide pools matrix .....41
3.3.3 Punch biopsy and sample processing................................................................42
3.3.4 Hematoxylin and Eosin (H&E) and immunohistochemistry (IHC) staining. ...42
3.3.5 Relative quantitation of gene expressions by real-time PCR............................43
3.3.6 Stimulation and measurement of effector cells in vitro ....................................44
v

3.4. Results .................................................................................................................... 44
3.4.1 Identification of peptide responses in an EIAV inapparent carrier...................44
3.4.2 Histopathology in response to injection with an individual reactive EIAV gp90
derived peptide. .................................................................................................48
3.4.3 In vitro and in vivo IFNγ gene expression following stimulation with
EIAVgp90 derived peptide pools ......................................................................48
3.4.4. Determination of in vivo cellular immune responses in four ponies at 6 months
post- infection with EIAV .................................................................................53
3.5 Discussion ............................................................................................................... 56
3.6 Acknowledgements ................................................................................................. 59
CHAPTER 4 Epitope shifting of gp90-specific cellular immune responses in EIAV
infected ponies .................................................................................................................. 60
4.1 Summary ................................................................................................................. 60
4.2 Introduction ............................................................................................................. 61
4.3 Materials and Methods............................................................................................ 63
4.3.1 Ponies, virus and experimental challenge .........................................................63
4.3.2 Production of synthetic peptides and construction of peptide pools matrix .....65
4.3.3 Determination of gp90 specific cellular immune responses over time in vivo .67
4.3.4 Determine gp90 specific T cells repertoire over time in vivo ...........................68
4.3.5 Stimulation and measurement of effector cells in vitro ....................................68
4.4 Results ..................................................................................................................... 69
4.4.1 Clinical Response to infection ..........................................................................69
4.4.2 Determination of gp90-specific cellular immune responses in EIAVD9 infected
ponies in vivo .....................................................................................................71
4.4.3 T cells are recruited to the injection sites..........................................................74
4.4.4 Gp90-specific cellular immune responses in EIAVD9 infected ponies in vitro.79
4.5 Discussion ............................................................................................................... 82
4.6 Acknowledgements ................................................................................................. 84
CHAPTER 5 Relationship between EIAV gp90 specific T cells recognition pattern and
epitope variability in EIAV newly infected ponies........................................................... 85
5.1 Summary ................................................................................................................. 85
5.2 Introduction ............................................................................................................. 86
5.3 Materials and Methods............................................................................................ 88
5.3.1 Ponies, virus and experimental challenge .........................................................88
5.3.2 Determination of EIAVD9 strain gp90 variation ..............................................89
5.3.3 Production of synthetic peptides and construction of peptide pools matrix .....92
vi

5.3.4 Gp90-specific T cells responses in vivo ............................................................93
5.3.5 Data Analysis ....................................................................................................94
5.4. Results .................................................................................................................... 95
5.4.1 Gp90-specific cellular immune responses in EIAVD9 infected ponies in vivo
over six months .................................................................................................95
5.4.2 Variability of gp90 in EIAV D9 strain ...............................................................95
5.4.3 Early recognized peptides were located in more variable regions of gp90 ......98
5.4.4 Gp90-specific cellular immune responses over time in newly constructed
consensus D9 (Con D9) vaccinated ponies ....................................................100
5.5 Discussion ............................................................................................................. 102
5.6 Acknowledgements ............................................................................................... 104
CHAPTER 6 Conclusion and future directions .............................................................. 105
6.1 Conclusion ............................................................................................................ 105
6.2 Future direction ..................................................................................................... 107
APPENDIX 1 Granzyme B-mRNA expression by equine lymphokine activated killer
(LAK) cells is associated with the induction of apoptosis in target cells ....................... 109
REFERENCE .................................................................................................................. 133
VITA ............................................................................................................................... 149

vii

List of Tables
Table 3.1. Peptides sequence comparisons among EV0, EV6 and EV13. ........................55
Table 4.1 MHC haplotypes ................................................................................................64
Table 4.2 Gp90 peptide Sequences ....................................................................................66
Table 5.1 MHC haplotypes ................................................................................................90
Table 5.2 Peptide sequence ................................................................................................91

viii

List of Figures
Figure.3.1 Identification of single peptide responses by peptide pool screening.. ............46
Figure.3.2 Confirmation of individual peptide reactivity in D64.. ....................................47
Figure.3.3 Histopathology of #37 peptide injection site from D64.. .................................51
Figure.3.4 Comparison between in vivo and in vitro IFNγ mRNA expression in response
to the peptide pools.. ........................................................................................52
Figure.3.5. Cellular epitope recognition in newly infected ponies.. ..................................55
Figure 4.1. Matrix of EV0 peptides.. .................................................................................65
Figure 4.2 Clinical and virological profiles of EIAVD9 infected ponies............................70
Figure 4.3 Summary of peptides recognition pattern in EIAVD9 infected ponies.. ...........72
Figure 4.4 IFNγ gene expressions in peptides injection sites in EIAVD9 infected ponies.73
Figure 4.5 Stable peptide recognition is seen in an inapparent carrier. ..........................75
Figure 4.6 Spectratyping analysis of intradermal injection sites indicates the recruitment
of peptide-specific T cells.. ..............................................................................76
Figure 4.7 IFNγ gene expressions detected by in vivo or in vitro assays. ........................81
Figure 5.1 Peptide Matrix.. ................................................................................................93
Figure 5.2 Summary of peptides recognition pattern in EIAVD9 infected ponies over six
months.. ............................................................................................................96
Figure 5.3 The relationship between peptides recognition pattern and the variability of
peptides overtime.. ...........................................................................................98
Figure 5.4. Comparison of the normalized Shannon entropy scores overtime.. ..............100
Figure 5.5 Peptide recognition pattern in ConD9 infected ponies over six months. .......101

ix

CHAPTER 1
Review of the Literature

1.1 EIAV is a model for lentivirus protection
1.1.1 EIAV structure
Belonging to lentivirus genus in the retroviridae family, equine infectious anemia
virus (EIAV) shares genetic and structural similarity with HIV, SIV and FIV (Casey et al.,
1985; Charman et al., 1976; Montelaro et al., 1988). EIAV is the most genetically simple
lentivirus with a genome size of 8.2kb (Leroux et al., 2004). Besides long terminal repeats
(LTR) which serve as the site of transcriptional initiation (Carvalho and Derse, 1993;
Sherman et al., 1988), the genome contains three major open reading frames, encoding
Gag, Pol, and Env proteins. The EIAV gag encodes four major internal structural proteins:
the matrix (MA) p15, the capsid (CA) p26, the nucleocapsid (NC) p11 and p9 (Hussain et
al., 1988; Stephens et al., 1986). These proteins are critical for virus assembly and budding
from infected host cells (Parent et al., 1995; Puffer et al., 1997; Strack et al., 2003;
Swanstrom and Wills, 1997). EIAV pol encodes the enzymatic proteins: RNaseH p66,
protease p12, dUTPase p15 and an integrase. The reverse transcriptase (p66/p51
heterdimer) is a proofreading-lacking enzyme and numerous mutations will be generated
in the viral genome each time the virus genome is replicated (Preston et al., 1988; Roberts
et al., 1988). These mutations provide the virus a molecular basis to evolve rapidly and
evade the host immune responses(Goodenow et al., 1989).
EIAV env encodes the surface unit (SU) gp90 and transmembrane (TM) gp45
glycoproteins. By non-covalently linkage, gp90 and gp45 form heterdimers. Gp45 is a
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transmembrane protein and helps anchor the complex in the lipid bilayer. Gp90 is the
surface protein which can bind the ELR1 receptor on equine macrophage and is essential
for virus entry (Zhang et al., 2005). Envelope protein sequences, especially gp90, are
highly variable in vivo (Kim and Casey, 1994). Longitudinal sequencing analysis of viral
RNA in plasma from a chronically infected pony revealed that gp90 sequence mutations
are not randomly distributed (Leroux et al., 1997). Eight hypervariable regions (V1-V8)
were identified and spanned the whole regions of gp90, where most of variable regions
were located in the carboxyl terminal of gp90. The variability the gp90 modulates the
antigenicity of the gp90 glycoprotein, which is the major target for the immune system.
Sequence changes help EIAV escape host immune control (Sponseller et al., 2007). Some
studies found that increasingly neutralization-resistant phenotypes emerged during
persistent infection (Zheng et al., 1997b).

Both gp90 and gp45 are extensively

glycosylated, with 18 predicted N-linked glycosylation sites on gp90 and four on gp45.
The glycosylation can also help to mask the virus from the immune system. Being the most
variable protein in the virus, envelope variation has become a major obstacle in the
development of a successful vaccine. Some studies found that even minor changes in
envelope sequences will significantly impact the outcome of vaccine efficacy.
In addition to the proteins coded by gag, pol and env, EIAV has three additional
short ORFs: Rev, Tat and S2. The Rev protein of EIAV is functionally similar to other
lentiviruses and regulates expression of incompletely spliced mRNAs, multimerizes, and
facilitates export of incompletely spliced viral mRNAs (Carpenter and Dobbs, 2010). The
EIAV Tat protein shares similar sequence to the other Tat proteins of lentiviruses, but are
located predominantly in the cytoplasm in horse (Rosin-Arbesfeld et al., 1994).
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Functioning as a transcription activator, Tat protein interacts with the viral LTR and
increases the transcriptional activity (Dorn and Derse, 1988). The S2 protein could be
detected in the cytoplasm during EIAV infection in horses(Yoon et al., 2000). Some studies
showed that S2 may function to organize the Gag protein during particle assembly. Recent
studies have indicated that S2 can interact with some proteins which influence the
trafficking and degradation of protein complexes in host (Covaleda et al., 2010). Other
studies have indicated that S2 is dispensable for viral replication in several equine cell
lines(Li et al., 1998), but is a key factor for viral replication and virulence in vivo (Li et al.,
2000). Based on these evidences, the EIAVΔS2 attenuated strain was developed by
insertion of two stop codons into the S2 gene of the infectious molecular clone EIAVUK(Li
et al., 2003). The insertion of two stop codons did not affect tat, env or the rev-response
element. A second deletion form EIAVΔS2 mutant (EIAVD9) was developed by insertion
of a nine base pair deletion in EIAVΔS2 (Craigo et al., 2007a). Studies have indicated that
these attenuated strains could serve as effective vaccines to prevent infection and clinical
disease following virulent challenge (Craigo et al., 2007c; Li et al., 2003). Also, these
designed attenuated vaccines could serve as models to investigate the mechanisms that
correlate with lentiviral protection.

1.1.2 Clinical course of EIAV infection
EIAV is a macrophage-tropic lentivirus which causes persistent infection,
characterized in three stages: acute, chronic and inapparent(Issel and Coggins, 1979).
Unlike its lentiviral relatives which slowly cause the collapse of the immune system and
death of the host due to opportunistic infection, EIAV infection could be effectively
12

controlled in horses (Clements et al., 1994; Oaks et al., 1998). Thus, one month post
experimental infection, most infected horses will develop an acute episode of disease
characterized by fever, diarrhea, edema, lethargy, anemia, thrombocytopenia and viremia.
During this acute phase, the immune system temporarily controls virus replication and
cause a drop of virus load in plasma. Subsequent EIAV escape from the immune response
causes another round of rapid viral replication, and clinical symptoms of EIA (Lichtenstein
et al., 1996; Sponseller et al., 2007). In the chronic phase, EIAV infected horses show
recurrent disease episodes. Sequencing of plasma virus from fever episodes indicated that
each occurrence of disease episode is caused by a noval viral quasispecies that is different
from the previous episode (Leroux et al., 1997; Zheng et al., 1997a).
After eight to twelve months of chronic disease, most horses will become
inapparent carriers free of clinical signs of disease while viral replication is maintained in
low levels in monocyte-rich tissue reservoirs. Administration of immunesuppressing drugs
can cause the reoccurrence of the disease(Kono et al., 1976). Sequencing of plasma virus
indicated that viruses from inapparent carriers were different from the last febrile episode,
indicating that EIAV still undergoes variability during inapparent carrier stage although
with a low tendency to cause any clinical disease(Leroux et al., 1997). Also, control of the
inapparent stage is not attributed to virus attenuation, as whole blood transfers from
inapparent carriers will cause disease in naïve horses. In addition, inapparent carriers are
resistant to challenge with other viruses, thus demonstrating the development of a high
level of protective immunity.
Compared with other virulent lentiviruses, EIAV is unique in that despite
aggressive virus replication and rapid antigenic variation, more than 90% of EIAV infected
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animals will end up in an inapparent carrier stage, in which the infected animals are free of
clinical diseases for the life span of the animal. Thus, the EIAV system has provided a
useful model to investigate mechanisms that correlates with protection.

1.2 Host defense mechanisms to viral infections
There is a stratified system of host immunity against invading pathogens. After the
physical barriers have been breached, there are two major categories of host immune
responses: innate and adaptive immune responses that can be directed against viral
infection.

1.2.1 Innate immune response against viral infection
The innate immune response is critical for the initial detection of invading viruses
and subsequent activation of the adaptive immune response. The innate immune response
recognizes viral components by pattern-recognition receptors (PRRs)(Akira et al., 2006).
There are three major classes of PRRs that involved in the recognition of viral components:
Toll like receptors (TLRs), RIG like receptors (RLRs) and NOD like receptors (NLRs)
(Mogensen, 2009) . These receptors recognize viral components, such as viral genomic
DNA, single strand RNA (ssRNA), double strand RNA (dsRNA), RNA with triphosphate
ends and viral proteins, and activate signaling pathways leading to the production of
proinflammatory cytokines, type I IFNs, and chemokines (Iwasaki and Medzhitov, 2004;
Kato et al., 2005). Proinflammatory cytokines and chemokines are important for
eliminating virus infection by stimulating inflammation and recruiting innate and acquired
immune cells to infection sites. Also, type I IFNs are critical cytokines produced after viral
14

infections. Type I IFNs are not only produced by professional innate immune cells, such
as dendritic cells (DCs) and macrophages, but also by other cells, such as fibroblasts. Type
I IFNs bind to a ubiquitous receptor, and activate signaling pathways that trigger the gene
expressions of more than 300 IFN-stimulated genes (ISGs)(Randall and Goodbourn, 2008).
These effector molecules can directly influence protein synthesis, cell growth and survival
and establish an antiviral state. For example, the protein ISG15 prevents virus-mediated
degradation of IRF3, enhance NF-κB signaling pathway, and modulate the immune
response (Harty et al., 2009). Also, type I IFNs induce maturation of DCs by up regulating
gene expression of co-stimulatory molecules such as CD80, CD86, CD40, and class MHC
I (Theofilopoulos et al., 2005). In response to certain viral infections, type I IFNs also
enhance NK cell cytotoxicity such that a broader range of virus-infected cells are lysed
(Yokoyama et al., 2004). Finally, type I IFNs cause stimulation and recruitment of
lymphocyte and monocytes at sites of infection by promoting vascular adhesion molecule
expression, induction of antigen-specific CD8+ T cell responses and induction of
chemokines(Honda et al., 2005).
Natural killer (NK) cells are another important component of innate immunity to
eliminate virus-infected cells. NK cells can respond to viral infection rapidly without prior
immunization, and are shown to play a critical role in controlling different types of viral
infections, such as lymphocytic choriomeningitis virus (Welsh, 1978), paramyxovirus
(Anderson et al., 1977), flavivirus (Macfarlan and White, 1980), and herpesvirus. NK cells
comprise 5–20% of all lymphocytes in peripheral blood and some specific organs, like the
spleen and liver. NK cell inhibition and activation are regulated by the differential
engagement of cytokines, inhibitory receptors, activation receptors and corresponding

15

ligands (Cerwenka and Lanier, 2001; Lanier, 1998). Inhibitory receptors on NK cells
recognize MHC class I molecules (Takei et al., 1997; Yokoyama et al., 1995). Normally,
inhibitory receptors provide dominant signals over those provided by activation receptors
when interacting with healthy cells expressing normal levels of MHC class I
molecules(Yokoyama, 1995). However, many types of viruses have developed ways to
interfere with the ability of MHC class I molecules to bind and present antigen-specific
peptides on the surface of cells (Beck and Barrell, 1988). Thus, NK cells selectively
recognize and kill virus-infected cells showing reduced levels of MHC class I molecules.
Upon activation, NK cells initiate apoptosis of target cells by granule exocytosis (Smyth
and Trapani, 1995; Trapani and Smyth, 2002) or Fas-FasL pathways (Nagata, 1997; Smyth
et al., 2003). Also, NK cells can kill infected cells via antibody-dependent cellular
cytotoxicity (ADCC) by engagement of their Fc receptors with the Fc portion of antibodies
bound to cell-associated antigens(Isitman et al., 2012). Besides cytotoxicity, NK cells can
secrete different sets of cytokines and chemokines, such as IFNγ, TNFα, IL-5, IL-10, IL13, granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage
inflammatory protein (MIP-1α)(Biron et al., 1999; Maghazachi, 2010). These NK cellreleased cytokines and chemokines are critical in downstream events of virus infection
control and affect the initiation and maintenance of subsequent adaptive immune
response(Biron et al., 1999).
Some cells from innate immune responses serve as a bridge between innate and
adaptive immunity. Viruses are engulfed by antigen presenting cells (APC), such as
dendritic cells (DC) or macrophages(Cella et al., 1997). The pathogens are processed and
pathogen-derived peptides are presented on the surface of the APC in the context of MHC.
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There are two major classes of MHC molecules: MHC I and MHC II. MHC I molecules
bind with peptides (9-10 amino acids) derived from intracellular pathogens, such as
viruses, and present to CD8+ T cells. MHC II molecules could bind with peptides (normally
13 amino acids) derived from extracellular pathogens, and present to CD4+ T cells. APC
deliver three different signals to naïve T cells for proliferation and differentiation.
Recognizing the MHC:peptide complexes on the surface of APC by T cell receptors is the
first signal. Signal 2 involves B7 proteins on APCs interacting with CD28 on T-cells. This
signal is quite critical for promoting T cell survival and expansion. Also, APCs produce a
mix of cytokines in response to different pathogens, and this third signal is primarily
involved in directing T cell differentiation into different sets of effector T cells.

1.2.2 Adaptive immune responses against viral infection
Once activated, T cells begin to produce IL2, which is critical for T-cell expansion.
Depending on the cytokines received, CD4+ T cells can differentiate into at least four
subsets: TH1, TH2, TH17 and Treg. For example, CD4+ T cells differentiation into the TH1
subset is promoted by IL12 and IFNγ, and differentiation into TH2 subset is promoted by
IL-4. Some recent studies have shown that CD4+ T cells are important components in some
viral infections(Sant and McMichael, 2012; Swain et al., 2012). It has been shown that
CD4+ T cells can trigger the recruitment of other lymphoid cells into infection sites
(Kumamoto et al., 2011). For example, CD4+ T cells can promote recruitment of DCs or
antigen-specific effectors to virus replication sites (Beuneu et al., 2006; Castellino et al.,
2006). Also, viral infections often induce strong effector CD4+ T cell responses that
provide support for expansion or function of B cell and CD8+ T cell responses(Elsaesser,
17

2009; Wiesel and Oxenius, 2012). Following viral infection, the TFH cells promote the
formation of germinal centers, the generation of memory B cells and plasma cells(Crotty,
2011). Interactions between CD40 (B cells) and CD40L (CD4+ T cells) are crucial for the
promotion of B cell activation and antibody production. Also, CD4+ T cells are required
to generate and enhance CD8+ T cell cytotoxic activity and maintain functions of memory
CD8+ T cell populations(Yi et al., 2009). Finally, CD4+ T cells function directly through
production of a mix of cytokines or cell-mediated cytotoxicity(Swain et al., 2012). One of
the most important cytokines CD4+ T cells secrete is IFNγ. IFNγ mediates a number of
different immunoregulatory effects to promote resistance to viral infection(Schroder et al.,
2004). It can promote T cell and B cell differentiation, activate CD8+ T cell cytotoxic
activity, and enhance the function of macrophages. Also, IFNγ can induce production of a
nitric oxide synthase (NOS) enzyme, which triggers the production of reactive oxygen
intermediates. These molecules function to modify a variety of molecules important for
replication of particular viruses.
Lacking a biosynthetic apparatus, all viruses need to replicate in the cytoplasm of
infected cells. Once inside cells, viruses are not accessible to antibodies, and activated
CD8+ T cells are in charge of eliminating these infected cells. Naïve CD8＋ T cells will
differentiate into cytotoxic T cells (CTLs). As mentioned above, the activation of CD8＋ T
cells also need three signals (interaction between TCR and MHC-peptide complex, costimulatory interactions and cytokines). Besides that, the fully activation of CD8＋ T cells
require more co-stimulatory activity which can be presented in two different ways. The
first way is stimulation provided by mature dendritic cells. These cells can stimulate CD8
＋

T cells to synthesize IL-2 and drive their own proliferation and differentiation. The
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second way is extra help provided by CD4 effector T cells. These CD4 effector T cells can
trigger dendritic cells to express higher levels of co-stimulatory activity. After activated,
CTLs circulate and identify infected cells which present virus peptides on the surface in
the context of MHC I molecules. Binding of the T cell receptor (TCR) of CTLs with
peptide:MHC I complex on infected cells will trigger the release of lytic granules from
CTLs into the synapse between CTLs and the infected cell. The granules contain potent
mediators which include pore-forming protein (perforin), cytotoxic cytokines, and
granzymes (a family of serine esterases)(Wong and Pamer, 2003).

Together these

mediators can induce death of the target cells via caspase-dependent and independent
apoptotic pathways. Perforin can help granzymes enter infected cells by making pores on
the infected cells or help granzymes bind with specific receptors on the surface of infected
cells. Once inside infected cells, granzymes will initiate a caspase dependent or
independent pathway, and trigger the infected cells to undergo apoptosis (Wiesel et al.,
2009). After that, the CTLs disengage with the target cells and move to the next infected
target. Additionally, CTLs also release cytokines, such as IFNγ and TNFα. IFNγ can inhibit
viral replication in various ways. For example, IFNγ could stimulate the expression of
MHC I molecules on the surface of infected cells, which will increase the chance that
infected cells are recognized by CTLs. Thus, CTLs act in a variety of ways to inhibit the
spread of virus and viral replication in infected cells.
Humoral immune responses also play an important role in controlling virus
infections (Sherman et al., 1983). Binding with circulating virus with its receptor (IgM), B
cells internalize the virus, process the virus inside cells, and finally present virus-derived
peptides on the surface in the context of MHCII molecules. Th cells recognize the MHCII-
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peptides complex and activate the B cells. The activated B cells will undergo class
switching and secrete virus-specific antibodies. Antibodies have multiple mechanisms to
remove viruses from circulation. Neutralizing antibodies are found in many virus
infections, and many studies have found a correlation between neutralizing antibodies and
protection. Some antibodies can coat the virus and bind the Fc receptors on the surface of
phagocytic cells, such as macrophages and neutrophils. The phagocytic cells will
phagocytize the virus and degrade viruses in the cells. Also, some antibodies have the
ability to activate the complement system, which also can enhance uptake by phagocytic
cells.

1.3 Immune responses associated with lentiviral infection
There are two major classes of virus: acute viruses (such as influenza, smallpox,
polio and measles) and chronic viruses (such as Epstein-Barr virus, cytomegalovirus,
hepatitis virus and HIV-1). Compared with the acute viruses that can be quickly cleared by
immune responses, chronic viruses normally establish persistent infection. Although much
knowledge has been created in the study of HIV, the exact immune response that is crucial
to control HIV infection is still unknown. Studies on other chronic virus and simian
immunodeficiency virus (SIV) indicated that both neutralizing antibodies and cellmediated immunity are effective against viral infection. In this section, we will mainly
focus on the immunity that mediates protection in lentiviral infections.

1.3.1 Humoral Immune Responses
A number of studies have investigated the role of humoral immune responses in
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controlling lentivial infection(Pantaleo and Koup, 2004). One of the most important
components of the humoral immune response against viral infection is neutralizing
antibodies, which can neutralize viral particles and prevent viral entry. Although some
early studies have found that neutralizing antibodies are present in long-term
nonprogressors (LTNPs), later studies have indicated a positive relationship between the
levels of HIV neutralizing antibody and plasma virus load. Also, continuous and rapid
generation of escape mutants decreases the efficacy of neutralizing antibodies in
suppressing viral replication. Thus, it is still unclear what role neutralizing antibodies play
in chronic HIV infection. Recent studies have indicated that cross-reactive neutralizing
antibodies arise in about 20% of HIV infected patients, and that these cross-reactive
neutralizing antibodies mainly target conserved regions and play as a critical role in the
protective immune responses to HIV infection (Liao et al., 2013; Mouquet and
Nussenzweig, 2013).
In additional to neutralizing antibodies, other types of antibodies also showed
effectiveness against lentiviral infection. It has been shown that non-neutralizing
antibodies can recruit NK cells and monocytes to mediate a stronger ADCC response
(Stratov et al., 2008). Binding to cell-associated antigens, the Fc portion of nonneutralizing antibodies engage with Fc receptors on the surface of innate immune cells,
and activate these cells to kill infected targets. In LTNPs, ADCC activity appears to be
higher compared to individuals with progressive disease (Alter and Altfeld, 2009).

1.3.2 Cellular mediated immunity (CMI)
One of the major hallmarks of HIV infection is the degeneration of CD4+ T cell
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population. Initially, it was thought that strong HIV-specific CD4+ T cell responses may
trigger the replication and dissemination of virus. However, recent studies revealed that
CD4+ T cells are clearly linked to immune control of HIV. The initial encounter with virus
triggers T cell expansion and it has been shown that Gag-specific T cells proliferate better
and establish a stronger antiviral activity (McKinnon et al., 2012). These virus-specific
CD4+ T cells responses are present in LTNPs. The ability of these virus-specific CD4+ T
cells to secrete IL-2 and proliferate upon stimulation is necessary for the preservation of
CD4+ T cells function in LTNPs.
Increasing evidence indicates that virus-specific cytotoxic T cell (CTLs) play an
important role in controlling lentiviral infection. Some evidence indicates that HIV
resistance is associated with specific class I HLA alleles. Since class I HLA alleles are
involved in presenting virus-derived peptides to CD8+ T cells, the association between HIV
resistance and some specific class I HLA alleles implies that CD8+ T cell responses play a
vital role (Heeney et al., 1999). The major antiviral mechanism of CD8+ T cells is to lyze
viral infected cells in which perforin and granzymes are major effector molecules. Some
studies have indicated that upregulated perforin expression of virus-specific T cell is
correlated with protection. Other studies have shown that the ability of CD8 T cells to load
lytic granules following antigen encounter is more effective in LTNPs (Betts et al., 2006;
Poudrier et al., 2012). Following depletion of CD8+ T cells in vivo, macaques had
significantly increased viral loads after challenge with SIV. Also, HIV-specific CTLs were
detected in long term non-progressers (LTNPs), and there was a correlation between CTLs
and low virus load (Betts et al., 2006). However, inconsistent results were found when
longitudinal studies were conducted. Additionally, no differences in the magnitude of HIV-
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specific T cell responses between persons with chronic progressive disease and LTNPs
were detected (Betts et al., 2001).
Indeed, there are multiple examples of detectable virus-specific T cell responses in
either infected or vaccinated individuals. However, not all virus-specific T cell responses
are necessarily associated with protection against lentiviral infection. Recent research
suggests that the quality, but not the quantity of the CD4+ and CD8+ T cell responses may
be much more important in protecting against lentivial infections. It has been found that
virus-specific T cells maintained a greater ability to produce multiple cytokines (IFNγ,
TNFα, MIP-1, CD107a and IL-2) in LTNPs compared to progressors. Also, studies
demonstrated that T cells recognizing epitopes (B27-KK10) related with the low viral load
were characterized by polyfunctional capabilities, increased clonal turnover, and superior
functional avidity.

1.3.3 Antigen sensitivity and TCR avidity
During viral infection, the responding T cells are a heterogeneous population that
differ in TCR expression, cytokine production profiles, cytotoxic activity, and homing
patterns. Recently, more studies have indicated an important role for antigen sensitivity
(AgS) in T cell control of lentiviral infections (Appay and Iglesias, 2011). AgS (also called
functional avidity) is the strength of T cell interaction with their targets, and is a composite
measurement of multiple interactions between the T cells and targets. It can be determined
by a functional assay with decreasing concentrations of antigen, and the AgS for that Tcell response is set at the concentration when 50% of the maximal functional response is
achieved (EC50). During acute infection, T cells with high AgS expand much faster than
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T cells with low AgS. Also, T cells with high AgS have the capability to produce higher
cytokines compared with low AgS T cells, and are more potent in suppressing HIV
replication in vitro.
There are several factors that influence the AgS, including TCR avidity (affinity of
TCR with peptide/MHC complex), interactions between TCR and the CD8 coreceptor, the
localization of the TCRs, the accessory molecules in lipid rafts, and the microenvironment
(cytokines)(Stone et al., 2009). TCR avidity is one of the most important factors that
influence AgS and efficacy of T cells against lentiviral infection (Bennett et al., 2010). For
situations such as HIV infection, where epitope variability is high, the T cell response needs
to adapt to the new variant or to be more cross-reactive, thus a greater breadth of TCRs
may be better for immune containment. The diversity of TCR is generated in the process
of combinatorial associations of germline V(D)J regions. The numbers of TCRs
recognizing one epitope may be more than one, and the clonotypes of TCR against the
same epitope may be highly variable between individuals. The TCR repertoire influences
its qualitative attributes. It has been found that different TCR clonotypes influence the
control of HIV-1 replication in vitro via cross-reactivity to epitope variants and enhance
ability to load and deliver perforin.
Although much evidence supports an important role of AgS and TCR avidity in
lentivial infection, there are divergent opinions as well. Firstly, due to the strong selection
pressure that T cells (high AgS) exert on the virus, the virus may mutate and escape from
the immune control. Second, T cells with high AgS rapidly proliferate after viral
stimulation, which may drive them towards T cells exhaustion and irreversible clonal
depletion. Lastly, not all evidence supports a positive correlation between the AgS and
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viral control. It has been found that some protective polyfunctional T cells actually have
low avidity for some HIV epitopes. In fact, these diverging data might indicate a
multifaceted basis of AgS.

In summary, although there are many promising data which indicate the importance
of CMI responses in controlling lentriviral infections, the key attributes of T cell mediated
protective immunity in lentiviral infection remain unclear. Considering the profound
heterogeneity and complication of T cells responses, assays to accurately identify those
responses are needed.

1.4 Questions regarding assays to measure CMI responses in lentivirus systems
Lots of data have shown that CMI is important in controlling lentiviral infections,
but precise parameters of CMI that correlate with protection are still unknown. One
possible interpretation is that the method used to measure CMI responses is questionable
(D'Souza and Altfeld, 2008). There are several ways to measure CMI responses: tetramerstaining assays can be used to determine the frequency of virus-specific T cells using
common MHC-restricted epitopes(Lieberman, 2004). Another commonly used assay is to
measure the IFNγ production by ELISPOT assay or intracellular cytokine staining (ICS).
ELISPOT has been widely used in both basic and clinical research to detect CMI responses
in HIV infected patients(Lieberman, 2004). Similarly, as in the tetramer-staining assay,
ELISPOT assays detect the frequency of IFNγ producing cells. However, recent studies
have started to call into question the reliability of ELISPOT assays for the measurement of
effective CMI responses. It has been found that though virus-specific T cells maintained
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high frequencies until late in disease, many of them have altered functional abilities
(Richmond et al., 2011), which both tetramer-staining and ELISPOT assays fail to detect.
Also, usage of only one functional indicator (IFNγ) may miss other effector responses.
Although IFNγ has antiviral effects, perforin and granzymes are more direct effector
molecules killing infected cells (Kuerten et al., 2008). Additionally, due to the low
frequency of antigen-specific T cell responses detected, it is very easy to generate false
positive, especially by unblinded researchers.
In addition to the limitations of methods used to detect CMI responses, there are
other issues of concern in lentiviral research field. The first concerns using consensus viral
sequences to construct antigens. Considering that the virus continuously mutates in vivo,
this method can only be an approximate measurement. Also, T cells recognizing earlier
virus may have better functional properties than the T cells recognizing later virus variants.
Indeed, some studies suggested that the use of consensus viral sequences underestimates
some T cells responses, and its breadth (Altfeld et al., 2003). Another problem is that some
studies investigating protective immunity are often cross-sectional. It has been found that
CMI responses sometimes are low and intermittent, which means sampling at a single time
point may underestimate transient responses.
Considering these methodological weaknesses, it is time to think about alternative
approaches. Choosing the right assays is especially important for investigating the
functional activity of T cells following lentiviral infections. Also, improved assays can
provide powerful tools for studying the protective mechanisms and further the development
of an effective vaccine against HIV.
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1.5 Immunodominance and immunodominance shifting
1.5.1 Immunodominance and the mechanisms of immunodominant shifting
With complex viral antigens, not all potential epitopes can be recognized by CD4
or CD8 T cells equally. Also, not all recognized epitopes elicit equivalent responses
(Yewdell and Bennink, 1999b). Normally, T cells focus on one or a few epitopes
(immunodominant epitopes). The rest of epitopes (subdominant epitopes) can still elicit T
cells responses, but at lower levels. During the acute virus infection, immune responses
function rapidly and eradicate the infection. At the same time, a pool of memory T cells
remain stable following viral clearance and confer long-lived immunological protection.
In the case of the chronic virus infection, however, most viruses can not be controlled
rapidly by the host’s immune responses. In this situation, a shift of immunodominance is
frequently detected evidenced by the changes in specificity, breath and magnitude of
epitopes-specific responses. In addition, the composition of the T cells pools may change
over time (Fuller et al., 2004; Wherry et al., 2003).
There are two major parameters that may shape the immunodominance: antigenrelated factors and T cell-related factors (Yewdell and Bennink, 1999a). Antigen
processing inside APCs may be the primary filter for epitope selection. After entry, virus
proteins will be degradated by the immunoproteasome, then the processed peptides will be
transported to the endoplasmic reticulum, bind with MHC molecules and finally translocate
to the cell surface. Any of steps involved antigen processing and final presentation to the
MHC complex can influence immunodominance. Also other factors, such as the kinetics
of viral protein synthesis, the overall abundance of the peptides, and the affinity and
stability of peptide/MHC complex can influence the hierarchy of T cell responses, as well
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(Yewdell and Bennink, 1999a). Additionally, in persistent viral infections, like HIV, where
antigens change overtime, immunodominance is largely influenced by the sequence and
availability of the peptide antigens. Mutations in the anchoring residues may significantly
reduce the affinity and stability of peptides binding with the MHC molecule. In this
situation, the presentation of the mutated peptide antigens to T cells may be diminished or
out-competed by other subdominant peptides.
For the T cell-related factors, it appears that the T-cell repertoire in the host can
shape the immunodominance as well(Gallimore et al., 1998a). During T cell development,
thymic selection shapes the diversity of the naïve CD8 T cell repertoire, and influences the
antigen-specific T cell precursor frequencies. In order to elicit T cell responses, a threshold
number of antigen-specific T cells with a certain affinity within the T cell repertoire is
required, thus the repertoire and composition of the pool of T cells are quite important in
shaping the initial response and subsequent memory pools. In chronic viral infection,
studies found that T cell may undergo clone exhaustion during persistent infections. The
antigen-specific T cells may succumb to deletion, leading to a change in these T cell
repertoire and epitope hierarchies.
It has been found that the initial immunodominant effector pools usually contribute
to the structuring of both primary response and the memory pools. Thus factors shaping
immunodominance might also influence viral loads, chronicity and outcome of infections.
It is thus a concern that different functions between epitope-specific responses exist. When
designing vaccines against chronic viruses, people should be aware of the kinetics changes
of epitope specific T cells responses, and which immune responses are the most effective
at mediating rapid control of primary infections as well as which responses are
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subsequently capable of conferring long-lived immunity.

1.5.2 Immunodominance and immunodominant shifting in lentivirus infection
The most conclusive evidence to show the association between T cell specificity
and virus control comes from the study of persons with one specific class I HLA allele
B*27. It was determined that individuals with class I HLA allele B*27 consistently
demonstrate delayed disease progression. Targeting of a single B*27-restricted Gag
epitope (KK10) was associated with lower viral load. However, the magnitude of Gagspecific T cell responses is actually lower in LTNPs than in persons with progressive
infection. Also, attempts to associate specific epitope responses with lentiviral control on
a population level fail to reveal a clear linkage. More studies have supported that protective
T cell epitope recognition should focus on conserved areas of the viral genome as T cell
responses were shown to be skewed towards variable peptides in early HIV-1 infection,
whereas towards more conserved peptides in chronic infection (Bansal et al., 2005;
Goulder et al., 2001; Liu et al., 2011c). Other studies have shown that HIV-specific T cells
responses could exert selection pressure and cause escape mutations rapidly in the primary
infection, but the virus escaped more slowly or was invariant in chronic infections
(Goonetilleke et al., 2009). These results indicated that immunodominant epitopes
recognized by T cells in the acute phase may serve as immunodecoys, whereas
immunorecessive epitopes may be more related to protection (Frahm et al., 2006a; van der
Most et al., 1997). HIV infection studies found that the frequency of naive T cell precursors
influenced the immunodominant recognition during acute infection. Also, antigen
sensitivity and TCR avidity can determine the immunodominance of HIV-specific T cells.
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Thus, when designing vaccines, it is important to know whether T cell recognition differs
between acute and chronic infection. If so, it is vital to determine which responses should
be generated and the appropriate antigens incorporated within a candidate vaccine.

1.6 Host immune response to EIAV infection
Although intensely studied, no effective vaccine against lentiviral infections is
available. In contrast to other lentivirus, horses gain immunologic control of the mutating
virus offering the possibility to study the protective mechanisms. The importance of the
immune response in controlling EIAV infection is supported by several pieces of evidence:
administration of immune suppressive drugs to inapparent carriers leads to the
recrudescence of EIA (Craigo et al., 2007a). Also, foals with severe combined
immunodeficiency (SCID) fail to control the initial viremic episode, and adoptive transfer
of EIAV-stimulated lymphocytes restores the control of viral replication in SCID foals.
Several studies have suggested that both humoral and cellular immune responses are
needed to control EIAV infection.

1.6.1 Humoral immune responses against EIAV infection
After being infected with EIAV for about three weeks, most horses typically
become seropositive(Perryman et al., 1988). The humoral immune responses are
predominantly focused on the viral envelope glycoproteins, and the antibody titer against
envelope is at least 10 fold greater than the antibody titer against the p26 protein. In EIAV
infected horses, neutralizing antibodies were originally thought to develop two months post
infection, but a recent study has identified neutralizing antibodies in the acute episode of
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EIAV infection (Mealey et al., 2005b). Neutralizing antibodies exert an immune selection
pressure on EIAV(Rwambo et al., 1990). Each disease episode during the chronic phase of
EIAV infection is associated with the emergence of a new neutralization-escape
quasispecies. Additionally, sequential EIAV variants that arise during persistent infection
showed increasing resistance to neutralization, which indicated that neutralizing antibodies
is one of the driving forces for immune selection (Howe et al., 2002). However, contrary
results about the role of neutralizing antibodies in controlling EIAV infection are also
reported. The level of neutralizing antibodies fluctuates markedly during the course of
infection without reaching a stable state. Also, a lack of correlation was detected between
the level of neutralizing antibodies and protection in some studies of vaccinated or infected
horses(Montelaro et al., 1998b). Facing virus evolution, immune responses may need time
to adapt (Hammond et al., 1997; Montelaro et al., 1998a). Hammond et al. described a
gradual evolution of the humoral response during the progression from chronic disease to
inapparent stages, and found that EIAV-specific antibody gradually matured from low
avidity, non-neutralizing, mainly focused on linear epitopes to high avidity, neutralizing
activity, mainly focused on conformational epitope (Hammond et al., 1997; Montelaro et
al., 1998a).

1.6.2 Cellular mediated immunity (CMI) against EIAV infection
The clearance of the primary viremia correlates with the appearance of EIAVspecific CD8+ T cells (McGuire et al., 1994a). Also, virus mutants escaping from EIAVGag and Envelope specific T cells are found (Mealey et al., 2003b). Cellular immune
responses against various EIAV proteins, such as envelope gp90 and gp45, the major core
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protein p26, can be detected (Mealey et al., 2005a). Also, T cell epitope mapping within
Gag matrix (p15), Capsid (p26), Pol, Envelope and Rev have been conducted (Chung et
al., 2005; Mealey et al., 2003b). However, vaccines designed to trigger Gag and Pol
epitope-specific immune responses are not effective at preventing infection or disease. A
true correlate of protection has not been found in EIAV infection. Lentiviruses have one of
the most rapidly evolving genomes. Both low fidelity of the lentiviral reverse transcriptase
and recombination of individual viral genomes within coinfected cells contribute to the
highly mutation rate. Comprehensive studies of EIAV genomic variation in experimentally
infected horses revealed that sequence changes predominantly occur in the envelope
glycoprotein. Detailed analyses of the evolution of EIAV indicated that each disease
episode correlates with the emergence of antigenic variants of the envelope in new
predominant quasispecies. A lot of studies have shown that the viral envelope protein has
a tremendous impact on the host immune responses to control viral infection and that the
mutations observed in envelope quasispecies represents a major challenge to lentiviral
vaccine development. Tagmyer has examined in detail the Th and CTL epitopes of EIAV
envelope protein in horses vaccinated with the live attenuated strain (EIAVD9) of EIAV
and found that six months post vaccination gp90-specific CTL and Th cells could recognize
peptides spanning the whole region of gp90, which may indicated a mature cellular
immune responses against gp90 (Tagmyer et al., 2008a; Tagmyer et al., 2007). No one has
studied how CMI evolves into this maturation status. A gradual evolution of the humoral
response during the progression from chronic disease to inapparent stages is detected,
indicating the maturation of the CMI response might also be a lengthy process.
Copyright © Chong Liu 2013

32

CHAPTER 2
Hypothesis and specific aims

The lack of a successful HIV vaccine accentuates the need to identify the protective
mechanisms involved in lentivirus infections. Equine infectious anemia virus (EIAV) has
been used as a model to investigate the protective immunity against lentivirus. Unlike HIV,
EIAV replication can be eventually controlled by the host’s immune systems, however, the
immune mechanism that correlates this protection has not been identified. While the
evolution of envelope-specific antibody responses following antigenic variation in the
envelope proteins have been investigated in great detail, little information is available
regarding the maturation of T cell responses to this virus. The existence of an effective T
cell response could exert selection pressure on the virus, forcing mutations to escape this
immune pressure. This would result in the disappearance of immunodominant T cell
antigens driving the T cells to recognize immunorecessive epitopes representing more
conserved amino acid sequences. We hypothesize that the envelope-specific recognition
will shift from immunodominant variable determinants to conserved immunorecessive
envelope determinants following the virus challenge.

Specific aim one: To develop a new in vivo method to identify envelope specific T
cell responses in EIAV infected ponies. Lots of data have shown that celluar immunity is
important in controlling lentiviral infections, but the true parameter that correlated with
protection is still unknown. One possible interpretation is that the methods we used to
measure celluar immunity are questionable. Characterization of cellular immunity to
lentivirus infection is usually done through the use of in vitro assays using peripheral blood
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mononuclear cells (PBMC). Considering that less than 2% of lymphocytes reside in blood,
PBMC responses may not fully reflect overall cellular immunity. Therefore, we developed
a skin test to monitor the EIAV envelope specific cellular immunity in vivo. This newly
developed method can be used to demonstrate EIAV peptide-specific immune responses
in vivo.

Specific aim two: To investigate the kinetics of envelope-specific T cell responses
in EIAV newly infected ponies. The ability of these lentiviruses to evolve, mainly in its
envelope protein, is the primary mechanism of lentivirus persistence To face this high
propensity for antigenic variation, we believe that immune responses also evolve. In order
to fully understand the kinetics of cellular immune responses, we synthesized forty-four
peptides, spanning the entire surface unit protein (gp90) of EIAV, and monitored the
peptide-specific T cells responses in vivo over six months following infection. This result
will provide an insight into the evolution of cellular immunity in EIAV infected horses,
that this shift in epitope recognition may associate with the control of viral replication and
the establishment of the inapparent carrier state.

Specific aim three: To determine the relationship between EIAV gp90 specific T
cells recognition pattern and epitope variability in EIAV newly infected ponies. In
persistent viral infections, especially like HIV in which antigens change overtime,
immunodominance is largely influenced by the sequence and availability of peptide
antigens. Mutations in the anchoring residues may significantly reduce the affinity and
stability of peptides binding with the MHC molecule. In this situation, the presentation of
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the mutated peptide antigens to T cells may be diminished or out-competed by other
subdominant peptides. In this study, the variability of EIAV gp90 in the attenuated EIAVD9
stain will be analyzed, and the epitope variability detected at 1, 3 and 6 months post EIAV
infection will be compared. This result will provide an insight of EIAV gp90 variation on
immune recognition, which may have profound effects on vaccine efficacy.
Copyright © Chong Liu 2013
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CHAPTER 3
The determination of in vivo envelope-specific cell-mediated immune responses in
Equine Infectious Anemia Virus-infected ponies.

Vet Immunol Immunopathol 148, 302-310 (2011)
Reprinted with permission
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3.1 Summary
Distinct from human lentivirus infection, equine infectious anemia virus (EIAV)infected horses will eventually enter an inapparent carrier state in which virus replication
is apparently controlled by adaptive immune responses. Although recrudescence of disease
can occur after immune suppression, the actual immune correlate associated with
protection has yet to be determined. Therefore, EIAV provides a model for investigating
immune-mediated protective mechanisms against lentivirus infection. Here, we have
developed a method to monitor EIAV-envelope specific cellular immunity in vivo. Fortyfour 20-mer peptides, representing the entire surface unit protein (gp90) of EIAV, were
combined into 14 peptide pools and intradermally injected into the neck of EIAV-infected
horses. An identical volume of saline alone was injected into a fifteenth site as a negative
control. After 48h, those sites with palpable infiltrations were measured prior to the
collection of 2mm and 4mm punch biopsies. Total RNA was extracted from each 2mm
biopsy for determination of CD3 plus interferon-γ (IFN-γ) mRNA expression by real-time
PCR. The 4mm skin biopsies were formalin-fixed and paraffin-embedded for
immunohistochemistry (IHC) staining for CD3, CD20, CD25 and MAC387 (macrophage
marker). Peripheral blood mononuclear cells (PBMC) were obtained prior to the injection
and tested for in vitro reactivity against the same peptides. Histological examination
showed that some of the envelope peptides elicited a lymphocytic cellular infiltration at the
injection site, as evidenced by positive staining for CD3. Peptide-specific increases in CD3
and IFN-γ gene expression were also detected in the injection sites. Furthermore,
differences were found between in vivo and in vitro responses to specific peptides. These
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results demonstrate a novel method for detecting in vivo cell-mediated immune responses
to EIAV-specific peptides that is readily applicable to other host/pathogen systems.

Keywords: EIAV; lentivirus; cellular immune responses; in vivo; envelope;
DTH
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3.2 Introduction
In contrast to lentivirus infections in humans, equine infectious anemia virus
(EIAV) replication is eventually controlled in most infected horses (Leroux et al., 2004).
Following initial infection, equids may exhibit recurring febrile viremic episodes
associated with high viral loads. After 12 to 24 months the frequency of disease episodes
begins to diminish and eventually the infected animal becomes free of overt clinical signs
and enters an inapparent carrier state that may last for many years (Craigo and Montelaro,
2010). Maintenance of this carrier state is dependent on active immune responses as
evidenced by the fact that immunosuppressive drugs can induce virus replication and the
recurrence of disease (Craigo et al., 2002b; Tumas et al., 1994). Inapparent carriers are
resistant to re-infection by other strains of EIAV, indicating that they have acquired a
certain degree of cross-reactive protective immunity (Montelaro et al., 1993). Therefore
the EIAV/horse system provides an opportunity for investigating mechanisms of protective
immunity against lentiviruses.
Both humoral and cellular immune responses appear to play important roles in
controlling EIAV infection. Virus-specific cytotoxic T cells (CTL) and neutralizing
antibodies are detected after the resolution of the acute phase of infection (Leroux et al.,
1997; McGuire et al., 2004). There is a progressive maturation of envelope-specific
antibody responses in EIAV infected horses, as characterized by the continuing increase in
titer, avidity and breadth of epitope reactivity throughout the first year of infection
(Hammond et al., 1997). However, little is known regarding the evolution of cellular
immune responses during EIAV infectoin. Until this study, characterization of cellular
immunity to EIAV infection has been investigated using in vitro assays (Chung et al., 2004;
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Mealey et al., 2005b). However, these in vitro assays may not detect alterations in cellular
immune responses occurring in vivo. While methods have been developed to monitor in
vivo immune responses in mice (Ashbridge et al., 1992; Nishino et al., 1994), guinea pigs
(Estrada et al., 1992; Mackall et al., 1993) and humans (Sitz et al., 1997a); similar
approaches have not been used to monitor cellular immune responses in horses. Here, we
have developed a method capable of defining epitope-specific cell-mediated immune
responses in EIAV-infected horses. Using this approach, specific differences in epitope
recognition between acutely infected and inapparent carrier were identified. There were
also differences between in vivo with in vitro responses to the peptides.

3.3 Materials and method
3.3.1 Animals, virus and experimental challenges
The overall methodology to evaluate CMI responses in vivo was developed and
optimized using a long-term, EIA inapparent carrier horse (D64) along with four ponies
(H40, H41, H42 and H43) experimentally infected within six months of the
commencement of these studies. D64 had been infected with the pathogenic viral strain
EIAVPV (Rwambo et al., 1990) and had not experienced a febrile episode for more than 7
years. All four ponies (H40, H41, H42 and H43) had the same sire and were challenged
with EIAV viruses (EV0, EV6 and EV13) derived from infectious molecular clones of
EIAVPV (Craigo et al., 2007d) . A non-infected pony (F31) was used as a negative control.
All animals were handled under the Guide for the Care and Use of Agricultural Animals in
Agricultural Research, U.S. Department of Agriculture, according to protocols approved
by the University of Kentucky Institutional Animal Care and Use Committee.
40

3.3.2 Production of synthetic peptides and construction of peptide pools matrix
Initially, forty-four peptides of 20 amino acids in length, overlapping sequential
peptides by 10 amino acids and spanning the entire surface unit protein (gp90) of EIAVPV,
were synthesized (GenScript USA Inc.,Piscataway, NJ, USA) and used to construct peptide
pools 1-7 and A-G as shown in Figure 3.1A. An additional 17 and 26 peptides speciﬁc for
EV6 and EV13, respectively, were synthesized for the construction of a new peptide pool
matrix for testing in the four infected ponies. All the peptides sequences were previously
published (Tagmyer et al., 2008b) and each peptide was HPLC-purified, and the purity was
confirmed by mass spectrometry (Tagmyer et al., 2007).
All peptides were dissolved in 100% dimethyl sulfoxide (DMSO, Sigma Aldrich,
St Louis, MO) at a stock concentration of 2 mg/ml. Later, the peptides were diluted in
saline for determination of the peptide specific responses in vivo. The optimal working
concentration for individual peptides was determined by serially diluting a known positive
peptide (#38) and injecting each dilution intradermally into the long-term infected
inapparent carrier (D64) at final concentration of 4.5, 1.5, 0.5, 0.17 and 0.06µg in 100 µl
saline. The positive peptide elicited responses at doses greater than 0.17µg (data not
shown). In contrast, there was no significant gene expression in response to the negative
peptide, #2 at the highest dose tested. Based on these preliminary results, each peptide was
tested at a dose of 0.5µg both individually and when incorporated into the peptide pools.
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3.3.3 Punch biopsy and sample processing
The neck of each horse was clipped and cleaned with 75% ethanol before
intradermal injection of 0.1ml peptide pools or single peptides. Saline alone was injected
to serve as the negative control. All injection sites were marked with an indelible marker
for identification. After 48hrs, the palpable infiltrations were measured at each injection
site and a 2mm skin biopsy was collected and stored in RNALater® (Ambion, Austin, TX)
in -20oC. A 4 mm skin biopsy sample was also collected and placed in 10% formalin for
subsequent paraffin embedding. The biopsy sites were closed using a single suture.

3.3.4 Hematoxylin and Eosin (H&E) and immunohistochemistry (IHC) staining.
Serial 6μm sections were cut from 4mm skin biopsy samples using Leica RM2235
Microtome and placed onto poly-L-lysine-coated glass slides for hematoxylin and eosin
(H&E) as well as immunohistochemistry (IHC) staining. H&E staining was performed
according to established protocols. IHC staining was performed using automated staining
system (BondMAX, Leica Biosystems, Buffalo Grove, IL). The paraffin embedded
biopsies were de-paraffinated in xylene, and rehydrated with decreasing alcohol rinses,
followed by heat epitope retrieval. An EDTA based buffer and surfactant (pH8.9-9.1) was
used for equine CD3, CD25 and MAC387 epitope retrieval. A citrate-based buffer and
surfactant (pH5.9-6.1) was used for equine CD20 epitope retrieval. Pan T lymphocytes
were detected using a cross-reactive, primary mouse anti-human CD3 antibody (Clone:
LN10) and activated T cells with a monoclonal anti-human CD25 antibody (Clone: 4C9).
B cells were detected using a primary mouse anti-human CD20 antibody (Clone: 7D1).
Neutrophils, monocytes, and macrophages were recognized by primary mouse anti42

macrophage marker antibody (Clone: MAC387). Following primary staining, slides were
incubated with a post primary blocking reagent (8mins), horse-radish peroxidase-labeled
polymer (8mins) and DAB substrate (10mins). After counterstaining with hematoxylin,
sections were dehydrated by increasing graded alcohols and mounted with cover slips.
Between additions of each reagent, washing steps were performed using Bond Wash
Solutions. All antibodies and reagents were purchased from Leica Biosystems (Buffalo
Grove, IL).

3.3.5 Relative quantitation of gene expressions by real-time PCR
The 2mm skin biopsy was transferred in 1.5ml eppendorf tube containing 0.5ml
RNA-STAT 60 (Tel-Test) and one 3 mm zirconium oxide bead (Retsch, Newtown, PA).
The biopsies were homogenized using a Retsch MM301 Ball Mill (Newtown, PA). All
samples were then placed on ice for 30 seconds before a second homogenization.
Afterwards, the suspended cell-lysates were transferred to another eppendorf tube with an
additional 0.5ml RNA-STAT 60 and stored at -20 ℃ for later RNA extraction. Total RNA
was isolated using the phenol: chloroform method (Chomczynski and Sacchi, 1987a). One

µg of RNA was dissolved in 41.5µl nuclease-free water (Qiagen, Valencia, CA) and
reverse transcribed into cDNA, as previously described (Breathnach et al., 2006) and stored
at -20 ℃ until later use.

Equine-specific, intron-spanning TaqMan primers and probes were used for RT-

PCR amplification. PCR reactions were performed as previously described (Liu et al.,
2011a). Amplification efficiencies were determined using Linreg (Ramakers et al., 2003)
and only samples with amplification efficiencies above 99% were included for further
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analyses. Beta-glucuronidase (β-GUS) was used as housekeeping gene and the △△CT
method (Livak and Schmittgen, 2001a) was used to determine relative gene expression

with saline injection site for each horse used as the calibrator. Relative quantity (RQ) was
calculated as 2-△△CT.
3.3.6 Stimulation and measurement of effector cells in vitro
Heparinized blood was collected prior to intradermal injections and peripheral
blood mononuclear cells (PBMC) were isolated using Ficoll-Paque PlusTM (Amersham
Biosciences, Piscataway, NJ) gradient centrifugation according to the manufacturer’s
protocol. The PBMC (3 x 106) were pulsed with 20ug/ml peptide pools for 4hrs, then
transferred to fresh RPMI-1640 (Gibco, Grand Island, NY) supplemented with 2.5% (v/v)
fetal equine serum (FES, Sigma, St. Louis, MO), 2mM glutamine (Sigma), 100U/ml
penicillin/streptomycin (Sigma), and 55 µM 2-mercaptoethanol (GIBCO, Grand Island,
NY). The peptide-stimulated PBMC were incubated in vitro for 4 days in a 24 well plate
at 37 ℃ in a 5% CO2 incubator. The cells were then pelleted and re-suspended in 1ml of

RNA-STAT 60 (Tel-Test) for further analysis of gene expressions by real-time PCR, as
described above.

3.4. Results
3.4.1 Identification of peptide responses in an EIAV inapparent carrier
Seven of the 14 peptide pools produced measureable swelling at the injection site
in the inapparent carrier, D64, at 48hrs post injection (Figure 3.1B). Furthermore, in biopsy
samples from all 7 of these injection sites there were significant increases in expression of
CD3 mRNA (Figure 3.1C). It was predicted based on the peptide pool matrix that D64
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could respond to a maximum of 12 individual peptides, as indicated by the grey boxes
(Figure 3.1B & C). However, subsequent experiments demonstrated these responses were
restricted to five peptides (4, 12, 37, 38, and 40) (Figure 3.2A). When these five sites were
biopsied and processed to determine CD3 gene expression by real-time PCR, all five
injection sites exhibited increased CD3 gene expression (Figure 3.2B). In contrast, there
was no evidence of increased CD3 gene expression at sites injected with peptides that
produced no measurable lymphocyte infiltration (data not shown).
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A

B

C

Figure.3.1 Identification of single peptide responses by peptide pool screening. (A) The
peptide components of each pool used for injection. (B) Predicted single peptide reactivity
as determined by the physical response and (C) CD3 gene expression for each pool.
Intersecting pools (gray shading) identify possible peptide specificities.
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A

B

Figure.3.2 Confirmation of individual peptide reactivity in D64. Single peptides 4, 12, 37,
38 and 40 were injected into the neck and physical responses measured after 48 hours.
Positive responses were indicated by measurable palpable infiltrations (A) and increased
CD3 gene expression (B).
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3.4.2 Histopathology in response to injection with an individual reactive EIAV gp90
derived peptide.
Biopsy samples from saline and a positive peptide (#37) injection site were selected
for histopathologic examination. H&E staining showed that injections of the peptide
induced vasodilation and recruitment of lymphocytes to the injections site (Figure 3.3A &
B). The recruited cells were mainly activated T lymphocytes as determined by CD3 and
CD25 staining (Figure 3.3C & D). There were few B cells or macrophages present (Figure
3.3E & F). No vasodilation or cell recruitment occurred in the sites where saline was
injected (Figure 3.3G & H). Likewise, CD3 and CD25 staining showed only resting T cells
randomly dispersed (Figure 3.3I & J) and few B cells or macrophages detected (Figure
3.3K & L) in the saline injection site. Similar results were seen for the other positive
peptides (data not shown).

3.4.3 In vitro and in vivo IFNγ gene expression following stimulation with EIAVgp90
derived peptide pools
Following intradermal injection of D64 with EIAVgp90 derived peptide pools IFNγ
gene expression was only significantly up-regulated within those sites receiving pools C,
E, F, G, 3, 4 and 6 (Figure 3.4). Therefore, as predicted the results closely mirrored those
obtained during transcriptional analysis of CD3. Stimulation of PBMC prepared from D64
with the same peptide pools produced increases in IFNγ gene expression in cells receiving
pools E, F, G, 3 and 6 as found in vivo. However, in contrast to the in vivo results there
was no increases in IFNγ gene expression to pools C and 4, although transcription of this
gene was up-regulated following the addition of pools A, 1 and 7 (Figure 3.4).
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50

Figure.3.3 Histopathology of #37 peptide injection site from D64. Sections (A-F) and
saline alone (G-L) ware stained with H&E (A,B,G,H) or with CD3 (C,I), CD25 (D, J),
CD20 (E, K) or MAC387 specific antibodies (F, L). Images (A and G) are shown at 4X
magnification and the boxed area represents area used for subsequent imaging at 40 X for
each of the antibody stains.
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Figure.3.4. Comparison between in vivo and in vitro IFNγ mRNA expression in response to the peptide pools. Peptide poolinduced IFNγ mRNA expression gene was detected by real-time PCR in biopsy samples (open bars) and from in vitro stimulated
PBMC (closed bars). The “+” and “x” indicate positive responses to the peptide pool in vitro and in vivo, separately.

3.4.4. Determination of in vivo cellular immune responses in four ponies at 6 months
post- infection with EIAV
The gp90-specific cellular immune responses in vivo were determined at 6 month
post challenge following the procedures described above. Three of the ponies H40 (peptide
pools H and 8), H41 (peptide pools D,E,H,1,3,4,8) and H42 (peptide pools
A,C,D,F,I,J,2,8,9) responded to gp90 peptide pools whereas H43 did not. Single peptide
reactivities were predicted, as shown in grey boxes in Figure 3.5, and individual peptides
were injected into the neck of the corresponding ponies. Positive physical reactions to
these individual peptides (indicated with * in Figure 3.5) were confirmed by increased CD3
and IFNγ gene expression (data not shown). As shown in Figure 3.5, all the positive
peptide pools contained at least one confirmed positive single peptide. Although some of
the peptides from the EV0, EV6, and EV13 viruses share similar sequences (Craigo et al.,
2007d), the ponies only recognized specific peptides from one virus. For example, H42
recognized single peptide #34 from EV6, but not single peptide #34 from EV0 or EV13
that share similar amino acid sequences, demonstrating the specificity of this in vivo assay
(Table 1).
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B

C
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Figure.3.5 Cellular epitope recognition in newly infected ponies. The original peptide pools
(Figure 3.1A) were supplemented with those peptides unique to the EV6 and EV13 viruses.
Those peptides in italics are unique to EV6 and those underlined are unique to EV13.
Palpable infiltration (mm2) were shown on the bottom and left sides of each figure.
Intersecting pools (gray shading) identify possible peptide specificities. Single peptides
with * are the peptides which could elicit positive responses in vivo.

Table 3.1 Peptides sequence comparisons among EV0, EV6 and EV13.

1

EV0
EV6
EV13

#34 peptide sequence
CD3 gene expression
PIFYTCNFTNITSCNNEPII
0
PIFYTCNFTNITSCNNESII
4
PMFYTCNFTSITSCNDESIT
0

1

2

IFNγ gene
expression2
0
16
0

Underscores indicate amino acid differences from the original EV0 peptide.
Relative gene expression determined using RT-PCR

2
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3.5 Discussion
For over a hundred years, the delayed-type hypersensitivity reaction has been used
for the diagnosis of both human and bovine tuberculosis (TB). After the intradermal
injection of a small amount of antigens in sensitized individuals, swelling and induration
become apparent between 24 and 72 hours. However, it was not until the 1940s when
Landsteiner and Chase were able to clarify that the reaction was mediated by cellular
instead of the humoral immune responses (Black, 1999). More recently, specific protein
epitopes have been identified which further refine this method (Whelan et al., 2010). The
DTH response has been used to assess either CD4+ or CD8+ T cells response to a variety
of antigens (Dietert et al., 2010; Poulter et al., 1982; Waksman, 1979). However, this
approach has rarely been used in horses (Hall et al., 2004). Further, only limited efforts
have been made to test the specificity and sensitivity of DTH responses to small peptides
in large animals. By contrast, DTH testing has been widely used in mice (Ashbridge et al.,
1992; Nishino et al., 1994) and guinea pigs (Estrada et al., 1992; Mackall et al., 1993), and
humans (Kran et al., 2012; Sitz et al., 1997b; Sitz et al., 1999) to evaluate epitope-specific
responses using small peptides. Here, we show that small peptides from EIAV gp90 can
elicit DTH responses within 48hrs post injection in EIAV infected horses. In order to
further characterize this DTH response in horses, we collected skin biopsies at the injection
sites for histologogy and gene expression analysis. The histological examination showed
an influx of CD3+, CD25+ T cells (Figure 3.3) within 48 hrs post-injection. Furthermore,
we found this cellular influx was directly correlated with increased CD3 and IFNγ gene
expression, a phenomenon not observed at injection sites receiving the saline control or
peptides that failed to stimulate palpable reactions. By employing a peptide matrix
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approach, followed by injection of individual peptides, it is possible to characterize cell
mediated immune responses at the level of individual protein epitopes. This provides for
the opportunity for comprehensive investigations of in vivo antigen-specific cellular
immune responses in EIAV infected horses.
While DTH responsiveness is often associated with IFNγ production in vitro
(Kapsenberg et al., 1991; Weynants et al., 1995), two peptide pools which induced DTH
responses in vivo did not up-regulate IFNγ gene expressions in vitro. This disparity
between in vivo and in vitro responses has also been reported in the case of HIV (Kvale
et al., 2005). There are several possibilities for these differences. By virtue of the sampling
method, PBMC represents a minor fraction of the total lymphocyte population. A low
frequency of antigen-specific cells thus reduces the chance of including such cells in a
blood sample. Since precursor expansion is required for the in vitro detection of specific
immune responses, both an infrequent precursor population and the likelihood that the T
cells will undergo apoptosis in vitro (Herbein et al., 1998; Shearer, 1998) further reduces
the sensitivity of this assay. By contrast, the DTH response involves the active recruitment
of antigen-specific T cells to the injection site, thus increasing the likelihood of a
measureable response even with a low frequency population. We also observed the
situation where peptide pools were recognized in vitro, but did not elicit a DTH response
in vivo. Such discordant responses may reflect a situation where the effector cell produces
IFNγ but not the other cytokines or chemokines required for a DTH response (Vestweber,
2007). Another possibility is that over time, the kinetics of development or loss of DTH
compared to IFNγ secretion differ (Black et al., 2001). The significance of this dichotomy
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between in vitro and in vivo responses in terms of protective immunity remains to be
determined.
Three of the newly infected ponies used in this study exhibited variable clinical
signs of EIA, characterized by fever, decrease in platelets, and increased virus load in
plasma. There appears to be a relationship between virus replication and the number of the
peptides recognized by these ponies. Thus, H42, which recognized multiple peptides, also
had multiple febrile episodes. These febrile episodes are typically associated with a
recurring high levels of viremia (Hammond et al., 1997). This indicates that the broader
peptide recognition was associated with repeated exposure to the virus, thus likely
expanding the pool of antigen-specific T cells. Since protective immunity eventually
occurs in EIAV-infected horses, this approach provides the opportunity to identify the
evolution of the protective mechanisms responsible for virus control in the EIAV infected
ponies, and perhaps as well for other lentivirus (Addo et al., 2003). By contrast, H43,
which did not show any clinical signs of EIA, did not recognize any peptides. We
occasionally encounter this situation where a particular equid effectively controls EIAV
replication while invariably having very weak antibody responses. Our current results
indicate there is a similarly weak CMI reactions in these seemingly resistant animals.
While the mechanism of this innate resistance remains unknown, it likely involves nonimmunological mechanisms based on these results.
In summary, we described a method to assess EIAV envelope specific cellular
immunity in vivo. Histological and gene expression analysis were used to confirm the
cellular nature of this response. As such, this approach offers an alternative to in vitro
detection of antigen-specific cellular immune responses.
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CHAPTER 4
Epitope shifting of gp90-specific cellular immune responses in EIAV infected ponies

4.1 Summary
EIAV has been used as a model to investigate protective mechanisms against
lentiviruses. Unlike other lentiviruses, EIAV replication can be eventually controlled in
most infected horses, leading to an inapparent carrier state free of overt clinical signs which
can last for many years. Maintenance of this carrier state is absolutely dependent on active
immune responses as evidenced by the fact that immunosuppressive drugs can induce the
recurrence of disease. However, the immune mechanisms that are responsible for this
control of infection are not yet identified. As the resolution of the initial infection is
correlated with the appearance of the virus specific CTL, it appears that cellular immune
responses play an important role. Since the virus undergoes rapid mutation following
infection, the adaptive immune response must also evolve to meet this challenge. In order
to fully understand the evolution of cellular immune responses, we synthesized forty-four
peptides, spanning the entire surface unit protein (gp90) of EIAV, and monitored the
peptide-specific T cells responses in vivo over six months following infection. Peptides
were injected intradermally and punch biopsies were collected for real-time PCR analysis
to monitor the cellular immune responses in vivo. Similar to the CMI response to HIV
infection, peptide-specific T cell recognition patterns in EIAV newly infected ponies
changed over time. While some peptides were recognized throughout the sampling period,
other peptides were only recognized at the later time points. Also, the response to some
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specific peptides disappeared after 6 months post infection. By contrast, peptide
recognition by an inapparent carrier (D64) was more stable.

4.2 Introduction
Equine infectious anemia virus (EIAV) has been used as a model for investigating
the underlying protective immune mechanisms against lentiviruses (Craigo and Montelaro,
2011). Following infection, most horses control their initial EIAV infection leading to an
inapparent carrier state (Hammond et al., 2000; Harrold et al., 2000). Immune responses
play an important role in controlling EIAV infection (Mealey et al., 2001b; Perryman et
al., 1988) since the administration of immunosuppressive drugs to inapparent carriers can
induce the recurrence of disease (Craigo et al., 2002a). The development of protective
immunity in EIAV-infected horses is protracted and often requires 6 – 12 months to
become established (Hammond et al., 2000; Harrold et al., 2000). Likewise, an attenuated
vaccine strain EIAVD9 provided protection against homologous virus challenges (Craigo
et al., 2007b), but optimum protective immunity was not seen until six months post
vaccination. Analyses of longitudinal serum samples from EIAV-infected horses displayed
an evolution of envelope-specific antibodies responses as measured by changes in avidity,
conformational recognition, and neutralization titers in EIAV infected horses (Hammond
et al., 1997; Hammond et al., 1999).
Cellular immune responses also appear important in controlling EIAV infections.
The appearance of EIAV-specific cytotoxic T lymphocytes (CTL) correlates with the
control of the initial viremia (McGuire et al., 2000). Additionally, CTL responses are
detected in inapparent carriers during the chronic phase of EIAV infection (Chung et al.,
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2005; Mealey et al., 2003a; Zhang et al., 1999). Both T helper (Th) and CTL epitopes have
been identified in the EIAV envelope protein of EIAV-infected horses (Tagmyer et al.,
2008a). Various studies have demonstrated EIAV Gag and Pol specific CTL responses
(Lonning et al., 1999; Mealey et al., 2005b) and identified broadly reactive T-cell epitopes
(Chung et al., 2004, 2005; McGuire et al., 2000). Nevertheless, the identification of
epitope-specific cellular immune responses that correlate with protection has proven
elusive (Mealey et al., 2009).

Further, not all potential epitopes in an antigenically

complex viral antigen can be recognized by CD4 or CD8 T cells (Gallimore et al., 1998b).
Also, not all recognized epitopes elicit equal responses. Typically, T cells responses focus
on one or a few epitopes (immunodominant epitopes) and the remainder of the epitopes
(subdominant epitopes) elicit limited responses (Yewdell and Bennink, 1999b). Most acute
viral infections involve the early recognition of immunodominant epitopes leading to the
eradication of the infection (Chisari and Ferrari, 1995; Perelson et al., 1993). By contrast,
in chronic viral infections there is a shift in T cell recognition from immunodominant to
subdominant epitopes (Fuller et al., 2004; Turner et al., 2005; Wherry et al., 2003). This
epitope shift is evidenced by increases in the specificity, breadth and magnitude of T cell
responses over time (Moskophidis et al., 1993).
Here, we monitored the peptide specificity of the cellular immune responses during
early EIAV infection. Over the initial six month post-infection, EIAV envelope specific T
cells responses were detected in vivo. Our results indicated that EIAV envelope specific T
cells undergo a shift in epitope recognition over time. This shift in epitope recognition may
be associated with the control of viral replication and the establishment of the inapparent
carrier state.
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4.3 Materials and Methods
4.3.1 Ponies, virus and experimental challenge
Sixteen ponies of mixed age and gender were used in this study. MHC haplotypes
were determined using polymorphic microsatellites, as previously described (Tseng, Miller
et al. 2010). Five ponies (G35, L132, H46, H38 and H32) shared the same MHC
microsatellite allele 219-252-280-172-247, three of the ponies (L126, L132 and I28) shared
the allele 211-260-268-166-247, and another three ponies (D49, H36 and H32) shared the
same MHC microsatellite allele 211-260-278-174-241 (Table 4.1). An inapparent carrier
infected with EIAV for more than six years was also included for comparisons.
The EIAVD9 was used as the challenge virus. The EIAVD9 stain contains two stop
codons and nine base pair deletion into the S2 gene of the infectious molecular clone
EIAVUK (Craigo et al., 2007b). Previous work has shown that that ponies infected with
EIAVD9 develop protective immunity against EIAV strains with a homologous gp90
sequence (Craigo et al., 2007b).
Ponies were inoculated intravenously with103 TCID50 of EIAVD9 (Craigo, Durkin
et al. 2007). All ponies were monitored daily for clinical symptoms of EIA throughout the
course of the 6 months study. Plasma samples from all animals were collected weekly and
stored at − 80ºC for later use to determine the levels of plasma viral RNA, as previously
described (Craigo, Durkin et al. 2007).
All animals were handled under the Guide for the Care and Use of Agricultural
Animals in Agricultural Research, U.S. Department of Agriculture, according to protocols
approved by the University of Kentucky Institutional Animal Care and Use Committee.
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Table 4.1 MHC haplotypes
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Horse ID
G35
L126
L132
F31
I28
H46
D49
H38
H36
H32
D55
I35
J30
L124
I33
L128

Virus
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9
EIAVD9

UMN-JH34-2-COR112-COR113-UM011-COR114
219-252-280-172-247
211-260-268-166-247
219-252-280-172-247
205-252-274-168-243
215-252-260-168-243
221-268-278-174-241
211-260-278-174-241
219-252-280-172-247
211-260-278-174-241
211-260-278-174-241
215-252-260-168-243
205-262-270-184-245
197-248-270-184-245
221-262-270-172-237
219-236-266-168-249
219-250-266-170-245

UMN-JH34-2-COR112-COR113-UM011-COR114
207-254-268-174-235
211-260-268-166-247
211-260-268-166-247
203-260-266-168-249
211-260-268-166-247
219-252-280-172-247
211-258-274-164-237
223-252-268-166-247
205-252-274-168-243
219-252-280-172-247
211-258-274-164-237
221-262-270-172-237
219-244-268-172-249
221-238-264-180-243
203-260-266-178-241
211-262-270-184-245

4.3.2 Production of synthetic peptides and construction of peptide pools matrix
Forty-four overlapping peptides of 20 amino acids in length spanning the entire
gp90 of EIAVD9 strain were synthesized (Table 4.2) and used to construct peptide pools
(Figure4.1). All peptides were HPLC-purified and dissolved in 100% dimethyl sulfoxide
(DMSO, Sigma Aldrich, St Louis, MO) at a stock concentration of 2 mg/ml. (Tagmyer et
al., 2007). The optimal working concentration for individual peptides was determined by
serially diluting a known positive peptide as previously described (Liu et al., 2012). A dose
of 0.5µg in 100ul saline was used for individual peptides and when incorporated into the
peptide pools.
g
1
2
3
4
5
6
7

A
1
15
29
43
14
28
42

B
3
17
31
2
16
30
44

C
5
19
33
4
18
32

D
7
21
35
6
20
34

p
E
9
23
37
8
22
36

F
11
25
39
10
24
38

G
13
27
41
12
26
40

Figure 4.1 Matrix of EV0 peptides. Forty-four peptides from EIAVD9 were synthesized. In
total, 14 peptides pools were constructed and each single peptide could be found in two
different peptide pools.
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Table 4.2 Gp90 peptide Sequences
EV0 peptide No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

EV0 peptide sequence
MVSIAFYGGIPGGISTPITQ
PGGISTPITQQSEKSKCEEN
QSEKSKCEENTMFQPYCYNN
TMFQPYCYNNDSKNSMAESK
DSKNSMAESKEARDQEMNLK
EARDQEMNLKEESKEEKRRN
EESKEEKRRNDWWKIGMFLL
DWWKIGMFLLCLAGTTGGIL
CLAGTTGGILWWYEGLPQQH
WWYEGLPQQHYIGLVAIGGR
YIGLVAIGGRLNGSGQSNAI
LNGSGQSNAIECWGSFPGCR
ECWGSFPGCRPFQNYFSYET
PFQNYFSYETNRSMHMDNNT
NRSMHMDNNTATLLEAYHRE
ATLLEAYHREITFIYKSSCT
ITFIYKSSCTDSDHCQEYQC
DSDHCQEYQCKKVNLNSSDS
KKVNLNSSDSSNPVRVEDVM
SNPVRVEDVMNTTEYWGFKW
NTTEYWGFKWLECNQTENFK
LECNQTENFKTILVPENEMV
TILVPENEMVNINDTDTWIP
NINDTDTWIPKGCNETWARV
KGCNETWARVKRCPIDILYG
KRCPIDILYGIHPIRLCVQP
IHPIRLCVQPPFFLVQEKGI
PFFLVQEKGIANTSRIGNCG
ANTSRIGNCGPTIFLGVLED
PTIFLGVLEDNKGVVRGNYT
NKGVVRGNYTACNVSRLKIN
ACNVSRLKINRKDYTGIYQV
RKDYTGIYQVPIFYTCNFTN
PIFYTCNFTNITSCNNEPII
ITSCNNEPIISVIMYETNQV
SVIMYETNQVQYLLCNNNNS
QYLLCNNNNSNNYNCVVQSF
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Region1
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
III
III
III
III
III
III
III
III
III

Table 4.2 (continued)
38
39
40
41
42
43
44

NNYNCVVQSFGVIGQAHLEL
GVIGQAHLELPRPNKRIRNQ
PRPNKRIRNQSFNQYNCSIN
SFNQYNCSINNKTELETWKL
NKTELETWKLVKTSGITPLP
VKTSGITPLPISSEANTGLI
ISSEANTGLIRHKRDFGISA

III
III
III
III
III
III
III

Footnote: 1: Gp90 are segmented into I,II,III regions equally

4.3.3 Determination of gp90 specific cellular immune responses over time in vivo
Identification of gp90-specific cellular immune responses in vivo was performed,
as described (Liu et al., 2012). Peptide pools or single peptides were injected intradermally
into the neck of each pony. After 48hrs, the palpable infiltrations were measured at each
injection site and a 2mm skin biopsy was collected and stored in RNALater® (Ambion,
Austin, TX). Skin biopsies were later homogenized using a Retsch MM301 Ball Mill
(Newtown, PA) and the suspended cell-lysates transferred to a 1.5ml eppendorf tube
containing RNA-STAT 60 (Tel-Test). Total RNA was isolated and 1 µg of RNA was
dissolved in 41.5µl nuclease-free water (Qiagen, Valencia, CA) and reverse transcribed
into cDNA. The cDNA was stored in -20oC until later use for real-time PCR or
spectratyping.
Intron-spanning TaqMan primers and probes for equine IFNγ were used for realtime PCR, as previously described (Liu et al., 2011b). PCR amplification efficiencies were
determined using Linreg (Ramakers et al., 2003) and only samples with amplification
efficiencies above 99% were included for further analyses. Beta-glucuronidase (β-GUS)
was used as the housekeeping gene. The saline injection site for each horse used as the
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calibrator (Liu et al., 2011b) and the relative quantity (RQ) for each target gene was
calculated as 2-△△CT (Livak and Schmittgen, 2001b). RQ values greater than 2 were
considered positive.

4.3.4 Determine gp90 specific T cells repertoire over time in vivo
The spectratyping method was used to identify peptide-specific clonal T cell
expansion in the injection sites . This assay was performed at the University of California
at Davis in the laboratory of Dr. Johanna Watson. Briefly, an equine T cell receptor (TCR)
β chain constant region-specific primer and twenty-four equine TCR Vβ-specific primers
corresponding to the complementarity-determining region 3 (CDR3) of the equine TCR β
chain were designed. Total RNA isolated from the intradermal injection sites was
converted into cDNA and used for the spectratyping. The PCR reactions were incubated
in triplicate wells at 95oC for 15 min, followed by 35 cycles of 94oC for 30s, 54oC for 30s
and 72oC for 30s. An ABI 3730 sequencer was used for determining amplicon length and
the size distribution analyzed using STRAND (Toonen and Hughes, 2001).

4.3.5 Stimulation and measurement of effector cells in vitro
Venous blood was collected via aseptic venipuncture into heparinized tubes, and
peripheral blood mononuclear cells (PBMC) isolated using Ficol-Paque PlusTM
(Amersham Biosciences,Piscataway, NJ) gradient centrifugation. After washed with PBS
for three times, PBMC were cryopreserved and stored in liquid nitrogen for later use.
Cryopreserved PBMC were thawed and approximately 2 x 106 were pulsed with
5ug/ml of the peptides in 1ml fresh RPMI-1640 (Gibco, Grand Island, NY) supplemented
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with 2.5% (v/v) fetal equine serum (FES, Sigma, St. Louis, MO), 2mM glutamine (Sigma),
100U/ml penicillin/streptomycin (Sigma), and 55 µM 2-mercaptoethanol (GIBCO, Grand
Island, NY). The peptide-stimulated PBMC were incubated in vitro for 4 days in a 24 well
plate at 37 ℃ in a 5% CO2 incubator. The cells were then pelleted and re-suspended in

1ml of RNA-STAT 60 (Tel-Test) for further analysis of gene expressions by real-time PCR,
as described above.

4.4 Results

4.4.1 Clinical Response to infection
Each pony seroconverted by 35 days post infection, as determined by commercial
ELISA kits (data not shown). There were no changes in rectal temperature (Figure 4.2A)
or platelet counts (Figure 4.2B) in any of the ponies post-infection. A low level of EIAVD9
replication, averaging 103–104 RNA copies/ml plasma, was detected during the first six
months post infection (Figure 4.2B).
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Figure 4.2 Clinical and virological profiles of EIAVD9 infected ponies. A) Rectal
temperature (°C) was measured daily in all EIAVD9 infected ponies. The average rectal
temperature was calculated and plotted. B) Viral p26 copies in the plasma (right axis) and
platelet counts (left axis) were determined at 3 week interval. The average p26 copies and
platelet counts for the 16 experimentally infected ponies are shown.
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4.4.2 Determination of gp90-specific cellular immune responses in EIAVD9 infected
ponies in vivo
Of the 16 ponies tested, 11 ponies showed gp90-specific responses following
intradermal inoculations. Screening all ponies with 44 EV0 peptides indicated that not all
peptides were recognized equally (Figure 4.3). Peptides located in regions I (#2, #6, #8,
#11, #14), II (#16, #21, #22, #23, #26, #28) and III (#30, #33, #34, #35, #36, #38, #41, #42,
#44) could elicit positive responses. Peptides #36 and #38 which are located in region III
were the most recognized peptides, by 4 and 5 ponies, respectively.
EIAV gp90-specific IFNγ gene expression in the intradermal sites was determined
at 1, 3 and 6 months post infection (Figure 4.4). Our results indicated that gp90-specific T
cells responses underwent both expansion and contraction. One month after infection, 7
ponies exhibited a gp90-specific IFNγ response. Five of the ponies recognized only one
peptide, and two ponies recognized two peptides (Figure 4.4A). Peptides #36 and #38 were
recognized by 2 and 4 ponies, respectively. Three months after infection, there were more
peptides in the middle and amino-terminus of gp90 recognized (Figure 4.4B). Six months
post infection, most ponies recognized more than one peptide and the recognized peptides
spanned the entire sequence of gp90 (Figure 4.4C). While some peptides were recognized
throughout the sampling period (L132 #36), other peptides were only recognized at the
later time points (G35 #26 #33 #36). Also, the response to some specific peptides
disappeared by 6 months post infection (D49 #38).
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Figure 4.3 Summary of peptides recognition pattern in EIAVD9 infected ponies. Eleven of the 16 ponies showed gp90 peptidespecific responses during the six month period of observation. The figure shows the accumulated recognition pattern for each
of the peptides tested.

Figure 4.4 IFNγ gene expressions in peptides injection sites in EIAVD9 infected ponies.
Ponies were tested at 1 (A), 3 (B) and at 6 (C) months post-infection. IFNγ gene expression
was determined using relative quantitation (RQ) and the results were log transformed.
Each point represents an individual pony’s response to the peptide.
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In comparison, an inapparent carrier which has been infected with EIAV for more
than six years showed more stable recognition. Thus, peptide C, E, F, G, 3, 4, and 6 elicited
a similar in vivo response over a 3 year period (Figure 4.5A). Furthermore, injection of
predicted single peptides (Grey boxes) demonstrated that this inapparent carrier recognized
the same peptides (4, 12, 37, 38 and 40) and produced IFNγ mRNA at the injection site at
both sampling times (Figure 4.5B).

4.4.3 T cells are recruited to the injection sites.
Further investigation of the diversity of recruited T cells was evaluated by
measuring the heterogeneity of the TCR CDR3 region at the injection site using
spectratyping, The total T cell CDR3 repertoire will typically follow a Gaussian
distribution whereas the recruitment/expansion of specific T cells clones to the injection
site will be represented as polyclonal skewed or oligoclonal distribution (Figure 4.6A).
CDR3 diversity was determined at the positive reaction sites following peptide #38
injection in pony H46 (Figure 4.6B). Following injection of the peptide, T cells with 22 of
the 24 TCR Vβ families were recruited to the site. Since not all Vβ families are represented,
and within specific Vβ families there is both clonal and oligoclonal responses, these results
are consistent with this being a T cell-specific response. By contrast, only three TCR Vβ
families were present in the saline only injection site, likely representing resident cells.
The breadth of T cells recruited to the injection sites was correlated with the magnitude of
peptide specific IFNγ response (Figure 4.6C). Also, there was evidence of an overall
reduction both in Vβ family utilization and the expression of IFNγ mRNA as the infection
progressed.
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Figure 4.5 Stable peptide recognition is seen in an inapparent carrier. A) Peptide pools
were screened in an inapparent carrier in 2010 and 2013. B) Those peptides eliciting a
positive response were biopsied and IFNγ gene expression determined using RT-PCR.
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Figure 4.6. Spectratyping analysis of intradermal injection sites indicates the recruitment
of peptide-specific T cells. A) When T cell clones undergo clonal expansion, skewed
distribution or oligoclonal distribution will be detected. B) Peptide specific T cells
repertoires in one pony which showed positive immune responses against peptide #38
determined by skin testing assays. Skin biopsies from both saline and #38 peptide injection
sites were collected and processed for spectratyping. In total, 24 primer pairs spanning
equine TCR b chain were used. C) Left axis shows IFNγ gene expression as determined by
real time PCR of punch biopsies. Right axis shows the percentage of T cell clones recruited
to the injection sites.
A
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4.4.4 Gp90-specific cellular immune responses in EIAVD9 infected ponies in vitro
Our results indicated that in newly infected ponies, gp90-specific T cells responses
underwent expansion and contraction during the first six months post EIAV infection. In
order to further confirm these changes, we also measured the peptide-specific T cell
responses in vitro (Figure 4.7). A total of 13 peptides were selected and tested in 6 ponies
at 1, 3 and 6 months post infection. In general, in vivo and in vitro assays showed similar
peptide-specific T cells recognition patterns overtime. The in vivo assay detected peptidespecific responses sooner compared to the in vitro assay. For example, peptide #36 was
recognized by L132 at 3 and 6 months post infection (both in vivo and in vitro), but only
the in vivo response was detected at 1 month post infection.
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Figure 4.7 IFNγ gene expressions detected by in vivo or in vitro assays. PBMC were
cultured with 5ug/ml specific peptides for 4 days for the determination of IFNγ gene
expression. Relative expression (RQ) over 2 was viewed as positive and the dotted line
indicates this threshold.
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4.5 Discussion
The ability of lentiviruses to alter their antigenicity allows for their persistence in
the infected host (Burns and Desrosiers, 1994; Craigo and Montelaro, 2010; Payne et al.,
1987). To counter this antigenic variation, the immune responses must also adapt (Nowak
et al., 1995a). Thus, in EIAV-infected horses, antigenic variation in the envelope gp90
results in escape variants that evade the neutralizing antibody response forcing the host to
develop specific antibodies against these new epitopes in order to control viral replication
(Montelaro et al., 1998a). While there is evidence that CTL responses also play a role in
restricting EIAV replication (McGuire et al., 2004), there have been no studies
investigating the effect of antigenic variation on these responses. Indeed, most studies
investigating T cell responses in EIAV infected horses involve few or singular time points
post-infection (Tagmyer et al., 2008a). Here we analyzed the dynamics of EIAV gp90
specific T cells responses over the first six months of the infection in ponies inoculated
with the EIAVD9 strain. We found that the T cell response undergoes expansion and
contraction in terms of gp90 epitope recognition.
There was evidence of an overall reduction both in Vβ family utilization and the
expression of IFNγ mRNA as the infection progressed. Exposure to viral antigen and
cellular division are needed to maintain virus-specific T cells during chronic infection
(Shin et al., 2007) and this dynamic shift in the immunodominant epitopes hierarchy in the
newly infected horses may be the result of mutations in specific epitopes leading to an
escape from T cell recognition. In the inapparent carrier, persistent recognition focusing on
the more conserved peptides results in a more effective T cell response and virus replication
is tightly controlled. However, it is also known that T cell escape mutations continue to
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occur in chronic infections, albeit at a lower frequency (Geels et al., 2003). Thus, other
factors might also account. In order to elicit T cell responses, a threshold number of
antigen-specific T cells with a certain affinity within the T cell repertoire must be required.
Studies found that T cells may undergo clonal exhaustion during persistent infections. The
antigen-specific T cells may succumb to deletion, leading to the changes of T cells
repertoire and epitope hierarchies. Spectratyping was used to identify the overall nature of
the T cells’ Vβ CDR3 repertoire involved in the peptide-specific responses (Lin and Welsh,
1998). We observed that not all Vβ families were represented, and within specific Vβ
families there were both clonal and oligoclonal distributions of the Vβ CDR3 repertoire.
Within each Vβ family, the predominant peak likely represented the dominant peptidespecific T cell clones with the smaller peaks representing other cells recruited to the site
non-specifically. As expected, the breadth of T cell recruitment to the injection sites, as
measured by Vβ CDR3 utilization, was correlated with the magnitude of IFNγ response
early in the infection.
In our study, we also found that not all ponies showed gp90 specific cellular
immune responses, although all ponies seroconverted one month post infection. This may
have been due to our use of a live attenuated virus, whose replication is significantly
decreased in horses (Craigo et al., 2005). This reduced viral replication may be less likely
to trigger robust immune responses (Peng et al., 2005). Several of the ponies also exhibited
elevated IFNγ production in the non-stimulated controls in vitro which could have been
due to active cell-mediated immune responses against other EIAV proteins such as the gag
or capsid proteins (Chung et al., 2004; McGuire et al., 1994b; Mealey et al., 2001a; Mealey
et al., 2005b). Also, it is important to note that we were only detecting those peptides
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present in the parental EIAVD9 strain of the virus. The true breadth of the T cell response
post-infection is likely much greater than we have detected. Likewise, the use of peptides
based on the consensus sequence of HIV underestimates the total T cell response (Altfeld
et al., 2003). Additionally, the peptides used in this study are 20 amino acids in length.
Since the typical length of a T cell epitopes is around 8 to 10 amino acids, and we cannot
exclude the possibility that our individual peptides might include multiple T cells epitopes.
This could account for the high number of Vβ families involved in the specific peptide
responses we measured.
In conclusion, our results indicate that T cell responses evolve during the early stage
of EIAV infection. The interaction between virus mutation and T cell evolution needs to
be further investigated.
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CHAPTER 5
Relationship between EIAV gp90 specific T cells recognition pattern and epitope
variability in EIAV newly infected ponies

5.1 Summary
EIAV has been used as a model to investigate protective mechanisms against
lentiviruses. Although studies have indicated that immune responses play an important role
in controlling EIAV infection, the immune mechanisms that are responsible for this control
are not yet identified. Since the virus undergoes rapid mutation following infection, the
adaptive immune response must also evolve to meet this challenge. In our previous study,
we found that gp90 specific T cells underwent expansion and contraction during the first
six months after infection with an attenuated EIAV strain (Chapter 4). Here, we want to
determine the relationship between EIAV gp90 specific T cell recognition and epitope
variability in newly infected ponies. We hypothesized that gp90 specific recognition will
shift from immunodominant variable determinants to conserved immunorecessive gp90
determinants following EIAV infection. Gp90 peptide-specific T cells responses were
monitored in vivo over six months following EIAV infection. At the same time,
approximately 87 virus clones from 25 ponies infected with EIAVD9 for six months were
analyzed. Finally, a new EIAV attenuated strain (EIAV ConD9) which contained a
predicted consensus gp90 sequence was tested. Our results indicate gp90 epitope specific
T cells target more variable regions of gp90 early post infection, whereas more conserved
regions of gp90 were identified six months after infection.
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5.2 Introduction

Equine infectious anemia virus (EIAV) has been used as a model for investigating
the underlying protective immune mechanisms against lentiviruses (Craigo and Montelaro,
2011). There are three clinical stages after EIAV infection: acute, chronic, and inapparent
carrier stages. One month post infection, most infected horses will develop an acute episode
of disease characterized by fever, diarrhea, edema, lethargy, anemia, thrombocytopenia
and viremia. During this acute phase, the immune system develops temporary control of
the virus infection resulting in a decrease in virus load in the plasma. In the chronic phase
of the infection, EIAV infected horses will show recurrent disease episodes. Sequencing of
viruses isolated from the plasma during febrile episodes indicated that each occurrence of
disease is caused by new viral quasispecies different from the previous episodes (Leroux
et al., 1997; Zheng et al., 1997a). After 6-12 months, most horses control the EIAV
infection and become inapparent carriers (Hammond et al., 2000; Harrold et al., 2000).
Immune responses play an important role in controlling EIAV infection during this
inapparent carrier stage (Mealey et al., 2001b; Perryman et al., 1988) as the administration
of immunosuppressive drugs can induce the recurrence of clinical disease (Craigo et al.,
2002a).
In a previous study, an attenuated vaccine strain EIAVD9 was shown to provide
protection against homologous virus challenges (Craigo et al., 2007b), but optimum
protective immunity was not realized until six months post vaccination. Thus, protective
immunity against EIAV infection is a lengthy process that likely involves the development
of immunity to viral variants (Hammond et al., 2000). Analyses of longitudinal serum
samples from EIAV infected horses identified an evolution of envelope-specific antibodies
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responses as measured by changes in avidity, conformational recognition, and
neutralization titers (Hammond et al., 1997; Hammond et al., 1999).
Cellular immune responses also appear important in controlling EIAV infections.
The appearance of EIAV-specific cytotoxic T lymphocytes (CTL) correlates with the
control of the initial viremia (McGuire et al., 2000). Most acute viral infections involve the
early recognition of immunodominant epitopes leading to the eradication of the infection
(Chisari and Ferrari, 1995; Perelson et al., 1993). By contrast, in chronic viral infections
there is a shift in T cell recognition from immunodominant to subdominant epitopes (Fuller
et al., 2004; Turner et al., 2005; Wherry et al., 2003). For example, initial HIV-specific T
cell responses are skewed towards immunodominant epitopes in the antigenically variable
regions of the virus in the initial stages of the infection, whereas subdominant epitopes in
the more conserved regions are recognized during the later stages of infection (Goulder et
al., 2001; Jamieson et al., 2003; Liu et al., 2013). Several studies indicated that protective
immunity to HIV likely requires T cell recognition of these subdominant epitopes in the
antigenically conserved regions of the virus (Frahm et al., 2006a; Goonetilleke et al., 2009)
and the added possibility that different cellular immune responses might also exist between
epitope-specific responses. In persistent virus infections, especially where antigens change
overtime, immunodominance is largely influenced by the sequence and availability of
peptide antigens.
In our previous study using the EIAV model, we found that peptide-specific T cell
recognition patterns changed over the initial six months of the infection. By contrast,
peptide recognition by a long-term inapparent carrier (D64) was more stable. Here, we
want to determine the influence of antigen variation on the epitope recognition in EIAV
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infected ponies. Virus clones from the ponies infected with the EIAVD9 strain for six
months were collected and the hypervariable regions of gp90 (V3 to V8) sequenced
(Leroux et al., 2001; Leroux et al., 1997). Also, a new EIAV attenuated strain which
contained a consensus gp90 sequence was used to determine the effect of concensus
sequences on T cell epitope recognition and immunodominance.

5.3 Materials and Methods
5.3.1 Ponies, virus and experimental challenge
Sixteen ponies were intravenously injected with 103 TCID50 of an attenuated
EIAVD9 strain (Craigo, Durkin et al. 2007). Also, a new live attenuated consensus (Con)
EIAVD9 strain constructed by insertion of a derived consensus gp90 into the backbone of
EIAVD9 virus was obtained from Dr. Ron Montelaro (Univ. of Pittsburgh). Eight ponies
were infected with this newly developed Con EIAVD9 strain virus. MHC haplotypes of the
ponies were determined using polymorphic microsatellites as previously described (Tseng,
Miller et al. 2010). For ponies receiving the attenuated EIAVD9 strain, five ponies (G35,
L132, H46, H38 and H32) shared the same MHC microsatellite allele 219-252-280-172247, three of the ponies (L126, L132 and I28) shared the allele 211-260-268-166-247, and
another three ponies (D49, H36 and H32) shared the same MHC microsatellite allele 211260-278-174-241 (Table 5.1). For the ponies receiving Con D9 strain, only two ponies
(G39 and G40) share the same MHC microsatellite allele 219-252-280-172-247 (Table 1).
All ponies were monitored for clinical symptoms of EIA throughout the course of
the 6 months study. Rectal temperature was monitored daily and platelet numbers
determined using an IDEXX QBC Vet Autoreader weekly. Plasma samples from ponies
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receiving EIAVD9 were collected weekly and stored at − 80ºC for later use to determine
viral RNA per milliliter of plasma. Gag-specific amplification primers were designed and
a quantitative real-time multiplex RT-PCR assay was used for analysis of viral RNA in
plasma samples.
All animals were handled under the Guide for the Care and Use of Agricultural
Animals in Agricultural Research, U.S. Department of Agriculture, according to protocols
approved by the University of Kentucky Institutional Animal Care and Use Committee.

5.3.2 Determination of EIAVD9 strain gp90 variation
Plasma was collected from each pony in the EIAVD9 infected group six months post
infection for virus sequencing. Virus sequencing was performed at the Department of
Microbiology and Molecular Genetics, University of Pittsburgh. The cloning and
sequencing of EIAVD9 gp90 were conducted as previously described (Craigo et al., 2010).
Approximately 87 EIAVD9 gp90 clones from 25 ponies infected six months were analyzed.
Multiple sequence alignments were conducted (http://www.genome.jp/ tools/clustalw/)
and gp90 amino acid sequence variability was determined, as described (Bansal et al.,
2005; Rodriguez et al., 2004). Normalized Shannon entropy scores were calculated for
each amino acid position in the protein alignment using the program Scorecons
(http://www.ebi.ac.uk/thornton-srv/databases/cgi-bin/valdar/scorecons_server.pl). Single
peptide variability was calculated as the mean of normalized Shannon entropy scores for
all amino acids located in the peptide.
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Table 5.1 MHC haplotypes
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Horse
UMN-JH34-2-COR112-COR113-UM011ID
Virus
COR114
UMN-JH34-2-COR112-COR113-UM011-COR114
G35
EIAVD9
219-252-280-172-247
207-254-268-174-235
l126
EIAVD9
211-260-268-166-247
211-260-268-166-247
L132
EIAVD9
219-252-280-172-247
211-260-268-166-247
F31
EIAVD9
205-252-274-168-243
203-260-266-168-249
I28
EIAVD9
215-252-260-168-243
211-260-268-166-247
H46
EIAVD9
221-268-278-174-241
219-252-280-172-247
D49
EIAVD9
211-260-278-174-241
211-258-274-164-237
H38
EIAVD9
219-252-280-172-247
223-252-268-166-247
H36
EIAVD9
211-260-278-174-241
205-252-274-168-243
H32
EIAVD9
211-260-278-174-241
219-252-280-172-247
D55
EIAVD9
215-252-260-168-243
211-258-274-164-237
I35
EIAVD9
205-262-270-184-245
221-262-270-172-237
J30
EIAVD9
197-248-270-184-245
219-244-268-172-249
L124
EIAVD9
221-262-270-172-237
221-238-264-180-243
I33
EIAVD9
219-236-266-168-249
203-260-266-178-241
L128
EIAVD9
219-250-266-170-245
211-262-270-184-245
G37
Con D9
205-252-274-168-243
205-262-264-170-239
G39
Con D9
219-252-280-172-247
209-254-268-178-251
G40
Con D9
203-260-266-168-249
219-252-280-172-247
I21
Con D9
215-264-270-172-249
219-238-266-178-241
I23
Con D9
205-262-270-184-245
215-262-272-168-255
I31
Con D9
197-248-270-184-245
219-236-266-168-249
K46
Con D9
UD*
UD*
L84
Con D9
221-268-278-174-241
207-262-272-168-255
*: Undetermined, Unable to find mare of K46, also could not find corresponding MHC alleles comparing with other existed known alleles

Table 5.2 Peptide sequence
EV0 peptide No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

EV0 peptide sequence
MVSIAFYGGIPGGISTPITQ
PGGISTPITQQSEKSKCEEN
QSEKSKCEENTMFQPYCYNN
TMFQPYCYNNDSKNSMAESK
DSKNSMAESKEARDQEMNLK
EARDQEMNLKEESKEEKRRN
EESKEEKRRNDWWKIGMFLL
DWWKIGMFLLCLAGTTGGIL
CLAGTTGGILWWYEGLPQQH
WWYEGLPQQHYIGLVAIGGR
YIGLVAIGGRLNGSGQSNAI
LNGSGQSNAIECWGSFPGCR
ECWGSFPGCRPFQNYFSYET
PFQNYFSYETNRSMHMDNNT
NRSMHMDNNTATLLEAYHRE
ATLLEAYHREITFIYKSSCT
ITFIYKSSCTDSDHCQEYQC
DSDHCQEYQCKKVNLNSSDS
KKVNLNSSDSSNPVRVEDVM
SNPVRVEDVMNTTEYWGFKW
NTTEYWGFKWLECNQTENFK
LECNQTENFKTILVPENEMV
TILVPENEMVNINDTDTWIP
NINDTDTWIPKGCNETWARV
KGCNETWARVKRCPIDILYG
KRCPIDILYGIHPIRLCVQP
IHPIRLCVQPPFFLVQEKGI
PFFLVQEKGIANTSRIGNCG
ANTSRIGNCGPTIFLGVLED
PTIFLGVLEDNKGVVRGNYT
NKGVVRGNYTACNVSRLKIN
ACNVSRLKINRKDYTGIYQV
RKDYTGIYQVPIFYTCNFTN
PIFYTCNFTNITSCNNEPII
ITSCNNEPIISVIMYETNQV
SVIMYETNQVQYLLCNNNNS
QYLLCNNNNSNNYNCVVQSF
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Con D9 peptide sequence

PFQNYFSYETNRSMHIDNNT
NRSMHIDNNTATLLEAYHRE

KKVNLNSSDSSIHVEDVED
SIHVEDVEDTTEYWGFKW
TTEYWGFKWLECNQTENFK
TILVPENEMVNINDNDTWIP
NINDNDTWIPKGCNETWARV

PFFLVQEKGIANTARIGNCG
ANTARIGNCGPTIFLGVLED

PIFYTCNFTNITSCNNESII
ITSCNNESIISVIMYETNQV
SVIMYETNQVQYLLCNNNNNS
QYLLCNNNNNSNNYNCVVQSF

Table 5.2 (continued)
38
39
40
41
42
43
44

NNYNCVVQSFGVIGQAHLEL
GVIGQAHLELPRPNKRIRNQ
PRPNKRIRNQSFNQYNCSIN
SFNQYNCSINNKTELETWKL
NKTELETWKLVKTSGITPLP
VKTSGITPLPISSEANTGLI
ISSEANTGLIRHKRDFGISA

PRPNKRIRNQNFNQYNCSIN
NFNQYNCSINNKTELETWKL

5.3.3 Production of synthetic peptides and construction of peptide pools matrix
Forty-four peptides, 20 amino acids in length, with 10 amino acids overlapping
and spanning the entire gp90 of EIAVD9 were synthesized by GenScript USA Inc.
(Piscataway, NJ, USA) (Table 5.2). An additional 15 peptides speciﬁc (Table 5.2) for gp90
of Con D9 EIAV strain were also synthesized for the construction of a new consensus
peptide pool matrix as shown in Figure 5.1. Each peptide was HPLC-purified, and the
purity was above 85% confirmed by mass spectrometry. All peptides were dissolved in
100% dimethyl sulfoxide (DMSO, Sigma Aldrich, St Louis, MO) at a stock concentration
of 2 mg/ml. Peptides were suspended in 100ul saline for determining peptide-specific
responses in vivo. The optimal working concentration for single peptides alone and within
a peptide pool was determined using 3 fold titrations in horse D64. The optimum
concentration was 5ug/ml.
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A

1
2
3
4
5
6
7

A
1
15
29
43
14
28
42

B
3
17
31
2
16
30
44

Matrix of EV0 Peptides
C
D
5
7
19
21
33
35
4
6
18
20
32
34

E
9
23
37
8
22
36

F
11
25
39
10
24
38

G
13
27
41
12
26
40

F
11
25
39
10
Con24
38

G
13
27
Con41
12
26
Con40

B

1
2
3
4
5
6
7

A
1
Con15
Con29
43
Con14
Con28
42

B
3
17
31
2
16
30
44

Matrix of Con D9 Peptides
C
D
E
5
7
9
Con19
Con21
Con23
33
Con35
Con37
4
6
8
18
Con20
22
32
Con34
Con36

Figure 5.1 Peptide Matrix. A) Forty-four original autologous peptides from EIAVD9 were
synthesized. B) Fifteen consensus peptides were newly synthesized. In total, 14 peptides
pools were constructed and each single peptide could be found in two different peptides
pools.

5.3.4 Gp90-specific T cells responses in vivo
Our in vivo method for assessing immune reactivity to specific peptides, described
in Chapter 3, was used to dissect the influence of virus variations on immune responses.
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In general, all infected ponies were screened for gp90 specific cellular immune responses
at 1, 3, and 6 months post infection. A 2mm skin biopsy was collected and homogenized
for later RNA extraction. Total RNA was isolated using phenol: chloroform method
(Chomczynski and Sacchi, 1987a). 1 µg RNA was dissolved in 41.5 µl nuclease-free water
(Qiagen, Valencia, CA) and transcribed into cDNA, as previously described (Breathnach
et al., 2006). The cDNA was stored in -20oC until real-time PCR analysis was performed.
IFNγ gene expression was determined by real-time PCR, as previously described
(Liu et al., 2011b). Equine-specific, intron-spanning TaqMan primers and probes were
used for RT-PCR amplification. Amplification efficiencies were determined using Linreg
(Ramakers et al., 2003) and only samples with amplification efficiencies above 99% were
included for further analyses. Beta-glucuronidase (β-GUS) was used as housekeeping gene
and the △△CT method (Livak and Schmittgen, 2001b) was used to determine relative gene
expression with saline injection site for each horse used as the calibrator. Relative quantity
(RQ) was calculated as 2-△△CT.
5.3.5 Data Analysis

One way analysis of variance (one way ANOVA) was used to determine
differences of normalized Shannon entropy scores over time. Unpaired t test was used to
determine differences between the normalized Shannon entropy scores of early and later
recognized peptides. Statistical significance was set at p < 0.05.
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5.4. Results
5.4.1 Gp90-specific cellular immune responses in EIAVD9 infected ponies in vivo over six
months
In summary, 11 ponies showed gp90-specific responses following intradermal
inoculations. One month post infection, 7 ponies exhibited gp90-specific T responses and,
as shown in Figure 5.2, most recognized peptides were found in the carboxyl terminal
region of gp90. After three months of infection, more peptides from the middle and amino
terminal end of gp90 were recognized. At six months post infection, most ponies could
recognize more than one peptide and these recognized peptides spanned the entire length
of gp90.

5.4.2 Variability of gp90 in EIAV D9 strain
Approximately 87 virus clones from the ponies infected with the EIAVD9 strain for
six months were collected and the hypervariable regions of gp90 (V3 to V8) sequenced
(Leroux et al., 2001; Leroux et al., 1997). As shown in Figure 5.3A, the locations of the
hypervariable regions of gp90 in EIAVD9 were quite similar as those in other EIAV strains
(Leroux et al., 1997). When the normalized Shannon entropy scores for each of the gp90
peptide was calculated (Figure 5.3B), the most variable peptides (#18, #19, #20) were
found to be located within the V3 region which contains a known principal neutralizing
domain (PND) (Leroux et al., 1997).
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Figure 5.2 Summary of peptides recognition pattern in EIAVD9 infected ponies over six
months. X-axis indicates gp90 peptides which could elicit positive T cells responses during
six months post infection. Y-axis indicated the number of ponies which could show gp90
positive responses.
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Figure 5.3 The relationship between peptides recognition pattern and the variability of
peptides overtime. A) The variability of gp90 in the attenuated EIAVD9 stain. X-axis
indicates amino acids location. Y-axis indicated the normalized Shannon entropy scores.
The lower the score, the more variable the regions are. The square boxes V3-V8 addressed
the variable and conserved regions of gp90 identified in pathogenic EIAV stain (Leroux et
al., 2001). B) Individual peptide variability. Y-axis indicated the average of the normalized
Shannon entropy scores for each peptide.

5.4.3 Early recognized peptides were located in more variable regions of gp90
When the normalized Shannon entropy scores of newly recognized peptides among
1, 3, and 6 months post infection were compared (Figure 5.4A), results indicated the
entropy scores of the newly recognized peptides in each time point increased over six
months (p=0.07). One month post infection, the peptides recognized were located in more
variable regions of gp90. In comparison, there were more peptides located in conserved
regions were recognized at six months post infection. Having noticed that not all ponies
showed gp90 specific immune responses in the first month post infection, we also separated
peptides into first recognized and later recognized peptides for each pony. As indicated in
Figure 5.4B, there was a significant increase of the normalized Shannon entropy scores
between first recognized and later recognized peptides (p=0.03).
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Figure 5.4. Comparison of the normalized Shannon entropy scores overtime. A)
Comparison of the normalized Shannon entropy scores among peptides recognized at 1, 3,
and 6 months. One way analysis of variance (one way ANOVA) was used to determine
differences of normalized Shannon entropy scores over time. B) Comparison of the
normalized Shannon entropy scores between peptides recognized early and later in each
pony. Unpaired t test was used to determine differences between the normalized Shannon
entropy scores of early and later recognized peptides. Statistical significance was set at p
< 0.05.

5.4.4 Gp90-specific cellular immune responses over time in newly constructed consensus
D9 (Con D9) vaccinated ponies
As the majority of the peptides recognized were located in the variable regions of
gp90 one month post EIAV infection and the more conserved peptides were recognized at
later time points, it seems likely that the hypervariable region of gp90 might serve as an
immune decoy. Deletion of these variable sequences might thus trigger T cells to recognize
more conserved sequences earlier. To test this hypothesis, a new consensus D9 live
attenuated EIAV strain was constructed and tested. Eight ponies were infected with this
new EIAV strain, and gp90-specific cellular immune responses in vivo were determined at
1, 3, and 6 months post infection.
Each pony seroconverted by 35 days post infection, as determined by commercial
ELISA kits (data not shown). There were no changes in rectal temperature or platelet
counts in the ponies post-infection. At one month post infection, two ponies (K46 and L84)
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showed positive gp90-specific cellular immune responses (Figure 5.5). All five peptides
were located in section III of gp90, and four of five peptides were also located in the more
variable regions of gp90. Six months post infection, more peptides located in sections I and
II corresponding to conserved regions were recognized. Thus, peptide #16 located in a
conserved was recognized by 3 ponies at six months post infection. Our results indicated
that this newly constructed attenuated ConD9 strain could elicit similar immune responses
as the attenuated EIAVD9 strain.

Figure 5.5 Peptide recognition pattern in EIAV ConD9 infected ponies over six months.
Six ponies were infected with EIAV ConD9 stain, and CMI responses in vivo against gp90
was monitored. Y axis indicated the total number of ponies recognizing each peptide.
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5.5 Discussion
The ability of lentiviruses to undergo antigenic variation, mainly in their envelope
proteins, is the primary mechanism of immune evasion in the infected host (Burns and
Desrosiers, 1994; Craigo and Montelaro, 2010; Payne et al., 1987). Previous investigations
of antigenic variation in EIAVD9 indicated that this virus also undergoes substantial
mutation following infection with the median divergence being around 1.89% from the
initial strain six months post inoculation (Craigo et al., 2010). During chronic infection,
EIAV envelope gp90 also mutates such that distinct conserved and variable regions can be
identified (Leroux et al., 2001; Leroux et al., 1997; Zheng et al., 1997a). In our study, we
found that the EIAVD9 strain undergoes similar changes in the conserved and variable
segments gp90, similar to other pathogenic EIAV strains.
To deal with this high propensity for antigenic variation, immune responses must
also adapt to the changing virus (Nowak et al., 1995a). In our previous study, we found
that gp90 specific T cells underwent expansion and contraction during the first six months
after EIAV D9 infection (Chapter 4). In this chapter, we wanted to determine the relationship
between EIAV gp90 specific T cells recognition pattern and epitope variability in EIAV
infected ponies. We found that T cell responses changed continuously in terms of peptide
recognition. Thus, one month post infection, most T cells targeted the variable regions of
gp90. By six months post infection, T cells recognizing peptides located in the conserved
regions emerged. Similar results were also found in an HIV study where HIV-specific T
cell responses were skewed towards variable peptides in early HIV-1 infection, whereas
more conserved peptides were recognized in chronic infections (Bansal et al., 2005;
Goulder et al., 2001; Liu et al., 2011c). Virus mutations leading to the loss of the initial T
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cell epitopes could be one of major reasons for the immunodominant recognition shifting
from variable peptides to more conserved peptides. T cell responses exert strong selection
pressure on the early recognized epitopes which have a greater tendency to mutate leading
to an escape from T cell recognition (Cao et al., 2003; Kelleher et al., 2001; Mealey et al.,
2004). Epitope entropy is thus correlated with the rate of the emergence of escape mutants.
Using consensus peptides, some studies have shown that responses to variable regions
diminish after acute infection and the disappearance of T cells responses was correlated
with the appearance of these T cell escape mutants (Jamieson et al., 2003; Liu et al., 2011c).
Studies of HIV-specific T cells responses have shown that similar selection
pressure causes escape mutations during the primary infection, but the virus escaped more
slowly or was invariant in chronic infections (Goonetilleke et al., 2009). Our findings
combined with others indicate that immunodominant epitopes recognized by the T cells
during the acute phase of the infection may serve as immunodecoys, whereas
immunorecessive epitopes may be more associated with long-term protection (Frahm et
al., 2006a; van der Most et al., 1997). We also tested a newly constructed attenuated ConD9
strain which contain a consensus gp90 sequence. To our surprise, ponies receiving Con D9
strain showed similar gp90 specific T cells recognition pattern during the first six months
post infection. Thus, gp90-specific T cells still recognized variable determinants one month
post vaccination and showed dynamic shifting to the immunorecessive epitopes in the more
conserved sequences six months post vaccination. Based on this finding, other factors may
also influence the immunodominant recognition. For example, T-cell repertoire in the host
can shape immunodominance as well. In order to elicit T cell responses, a threshold number
of antigen-specific T cells with a certain affinity within the T cell repertoire must be
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required. In chronic viral infection, studies found that T cell may undergo clone
exhaustions during persistent infections. The antigen-specific T cells may succumb to
deletion, leading to the changes of T cells repertoire and epitope hierarchies.
Importantly, our data did not show T cells exclusively targeting variable peptides
during the acute phase of the infection, but rather an expansion of responses to the more
conserved peptides during the chronic stage of the infection. When designing vaccines, it
is important to know whether T cells recognition differs between acute and chronic
infection. If so, it is vital to determine which responses should be generated and
incorporated within a candidate vaccine.
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CHAPTER 6
Conclusion and future directions

6.1 Conclusion

More than 30 million people are infected with HIV, with the estimated AIDSrelated deaths around 1.8 million people in 2009. The development of a successful AIDS
vaccine is urgently needed to protect and treat HIV infection. However, there are many
challenges to develop a successful AIDS vaccine. Vaccines are a potent tool to prevent and
treat different infectious diseases (Pantaleo and Koup 2004). One reason for the failure of
AIDS vaccines is that the nature of an effective immune response that correlates with
protection is unknown (Klausner, Fauci et al. 2003; Pantaleo and Koup 2004). The
complexities of AIDS vaccine research, coupled with the lack of a successful human AIDS
vaccine, accentuate the need for animal models to investigate the protective immune
mechanisms against lentiviral infection.
Identified in 1843, EIAV was later classified as a lentivirus (Craigo and Montelaro
2011). Distinct from other lentiviruses, EIAV infection can be controlled by the horses’
immune system. This naturally gained protective immunity makes EIAV a good model for
investigating the underlying protective immune mechanisms against lentivirus. It has also
been shown that an attenuated virus vaccine (EIAVD9) could provide 100% protection
against homologous virus challenge (Li, Craigo et al. 2003; Tagmyer, Craigo et al. 2007),
such that this attenuated virus vaccine could serve as a model to investigate the virusspecific immune responses associated with the enduring broadly protective immunity.
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Up till now, the greatest challenge for the development of an effective HIV vaccine
might be the envelope antigenic variation and associated immune evasion of lentiviruses.
Work on EIAV has shown that envelope variation is a primary mechanism responsible for
immune evasion such that even minor changes in envelope protein sequences can markedly
affect recognition and protective immunity (Craigo, Zhang et al. 2007). To face this high
propensity for antigenic variation, we believe that immune responses also evolve (Nowak
et al., 1995a). The major focus of this dissertation is to evaluate the changes of cellular
immunity in EIAV infected ponies, and the influence of gp90 antigenic variation on
cellular immune recognition. Using a new established in vivo assay, we found that gp90specific T cell responses underwent expansion and contraction during the first six months
post EIAVD9 infection. Further analysis of the influence of sequence variations on T cells
recognition indicated that T cells recognition was skewed towards variable peptides in
early EIAV infection, whereas towards more conserved peptides after 6 months infection.
In contrast, the peptide recognition pattern in an inapparent carrier was more stable over
three years.
Comparison of the MHC haplotypes showed that only L132 and H46, D49 and H36
shared the same haplotypes. The major length of T cells epitopes are usually around 8 to
10 amino acids, and we could not exclude the possibility that our peptides (20 amino acids
length) might include multiple T cells epitopes. Also, broadly recognized T cells epitopes
are detected in EIAV infected ponies (Chung et al., 2004), ponies with different MHC
haplotypes may also recognize the same epitopes. Our finding indicated that cellular
immune responses in EIAV infected ponies undergo a gradual maturation during the early
infection, and the stable recognition in the apparent carrier indicates an enduring protective
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immunity in the chronic infection stage. The epitope shifting from variable to conserved
regions implies that T cells recognizing conserved epitopes are more important in
controlling EIAV infection. When designing vaccines, it is important to know whether the
T cells recognitions differ between acute and chronic infection. If so, it is vital to determine
which responses should be generated and incorporated within a candidate vaccine. Based
on our results and others, it seems that immune responses targeting subdominant conserved
regions are more critical component against lentiviral infections (Frahm et al., 2006b).

6.2 Future direction

Understanding the mechanisms that may influence this immunodominant and
immunodominant shifting will provide useful information for vaccine development. There
are two major parameters that may shape the immunodominance: antigen-related factors
and T cell-related factors. In persistent viral infections, especially like HIV which antigens
change overtime, immunodominance is largely influenced by the sequence and availability
of peptide antigens. Mutations in the anchoring residues may significantly reduce the
affinity and stability of peptides binding with the MHC molecule. In this situation, the
presentation of the mutated peptide antigens to T cells may be diminished or out-competed
by other subdominant peptides. T cells responses exerted strong selection pressure on the
early recognized epitopes and the selected epitopes have a high propensity to mutate and
result in T cells escape (Cao et al., 2003; Kelleher et al., 2001; Mealey et al., 2004).
Although T cell escape has been identified in EIAV infected horses in the previous study,
the interaction between T cells escape mutant and T cells recognition pattern changes need
to be further studied.
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Also, it appears that the T-cell repertoire in the host can shape the
immunodominance as well. In order to elicit T cell responses, a threshold number of
antigen-specific T cells with a certain affinity within the T cell repertoire must be required.
In chronic viral infection, studies found that T cell may undergo clone exhaustions during
persistent infections. The antigen-specific T cells may succumb to deletion, leading to the
changes of T cells repertoire and epitope hierarchies. Also, peptide specific T cells detected
early have high affinity toward the epitopes. These T cells with high affinity could compete
with other T cells and apply selection pressure on the virus (Lichterfeld et al., 2007; Mealey
et al., 2003a; Nowak et al., 1995b). In our study, we found that the epitope specific T cells
repertoire correlates with the magnitude of T cells responses in vivo in two ponies. Whether
the T cells receptor repertoire and T cells affinity have any correlation with this
immundominant recognition and immunodominant shifting need to be further investigated.
Copyright © Chong Liu 2013
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APPENDIX 1
Granzyme B-mRNA expression by equine lymphokine activated killer (LAK) cells is
associated with the induction of apoptosis in target cells

Veterinary Immunology and Immunopathology 143, 108-115 (2011)
Reprinted with permission
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Abstract
Lymphokine-activated killer (LAK) cells are a subset of cytotoxic cells capable of lysing
freshly isolated tumor cells. While LAK activity is typically measured using the

51

Cr-

release assay, here we used a non-radioactive flow cytometric method to demonstrate
equine LAK activity. Equine peripheral blood mononuclear cells (PBMC) were stimulated
in vitro with recombinant human interleukin 2 (hIL-2) to generate LAK cells. An equine
tumor cell line, EqT8888, labeled with carboxyfluorescein succinimidyl ester (CFSE) was
used as target cells. Following incubation of the targets with different concentrations of
LAK cells, Annexin V was added to identify the early apoptotic cells. With increasing
effector to target cell ratios, EqT8888 apoptosis was increased.

We also measured

interferon-gamma, granzyme B and perforin mRNA expression in the LAK cell cultures
as possible surrogate markers for cytotoxic cell activity and found granzyme B mRNA
expression correlated best with LAK activity. Also, we found that the reduced LAK
activity of young horses was associated with decreased granzyme B mRNA expression.
Our results indicate that fluorescence-based detection of LAK cell activity provides a
suitable non-radioactive alternative to

51

Cr-release assays and mRNA expression of

granzyme B can be used as surrogate marker for these cytotoxic cells.

Keywords: equine LAK cells; flow cytometric assay; granzyme B; perforin;
IFNγ; real-time PCR
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1. Introduction
Cell-mediated cytotoxicity (CMC) is an important effector mechanism directed against
transformed and infected cells. Natural killer (NK), lymphokine activated killer (LAK) and
cytotoxic T lymphocytes (CTL) are examples of these effector cells. The granules of
cytotoxic lymphocytes contain potent mediators which include pore-forming protein
(perforin), cytotoxic cytokines, and granzymes (a family of serine esterases). Together
these mediators can induce death of the target cells via caspase-dependent and independent
apoptotic pathways (Young et al., 1988). While the

51

Cr release assay has been widely

used to demonstrate CMC (Brunner et al., 1968), this assay has several disadvantages
including the use of a radioactive isotope, high levels of spontaneous release by some
targets, and a failure to identify the mechanism of cytotoxicity. Since the 51Cr-release assay
only detects the late phase of cytotoxicity, it does not distinguish between apoptosis and
other mechanisms of cell lysis. Alternative methods using non-radioactive approaches can
overcome some of these limitations.

Flow-cytometric methods have been developed which use fluorescent regents to detect
target cell killing either as an increase in membrane permeability (Flieger et al., 1995)or
by changes in membrane morphology associated with apoptosis (Goldberg et al., 1999). In
addition to avoiding the use of radioactive reagents, this approach offers overall greater
sensitivity than the 51Cr-release assays (Aubry et al., 1999) and allows for detection of both
early and late phases of cell killing (Vermes et al., 1995).
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An alternative approach to quantitating CMC is the direct detection of the cytotoxic cell
population using antibodies either against specific cell surface proteins (Kim et al., 2007)
or the effector molecules involved in target cell lysis. While cell surface staining can
identify cells with cytolytic potential (e.g. NK, CD8+ T cells, etc), it fails to detect effector
function. Detection of specific effector molecules has been used to identify functional
cytotoxic cells. Interferon-gamma (IFNγ) has frequently been used in equine research as
a surrogate marker for cytotoxic cell activity (Breathnach et al., 2005; Ellis et al., 1997;
Paillot et al., 2006). However, studies in other species have shown that IFNγ production
does not correlate well with cytotoxic activity (Calarota et al., 2006). Given these findings
and the fact that non-cytolytic CD4+ T cells can also produce IFNγ, we believe better
surrogate markers for equine cytotoxic effector function are needed. Granzyme B and
perforin, two major effector molecules in the granule-mediated cytolytic pathways, are
better markers since studies have shown that their expression correlate well with cytotoxic
activity in PBMC cultures (Shafer-Weaver et al., 2003; Zuber et al., 2005)
In this report, we use a flow cytometric method for the characterization of equine LAK
cell-mediated cytotoxicity using CFSE-labeled target cells and PE-Annexin V to identify
target cells in the early apoptotic phase. We also examined three surrogate markers for
LAK activity; IFNγ, granzyme B and perforin mRNA expression and found that granzyme
B mRNA expression correlates best with cytotoxic activity of LAK cells.
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2. Materials and method
2.1. Horses
Five 10 year old horses were used for the initial optimization of the flow cytometric and
gene expression assays. Five additional 1 year old mix-breed horses were used to compare
LAK activity and gene expression in the different aged horses. All horses were owned by
the Department of Veterinary Science, University of Kentucky and handled in accordance
with the Guide for the Care and Use of Agricultural Animals in Agricultural Research, U.S.
Department of Agriculture. All research procedures were approved by the Institutional
Animal Care and Use Committee of the University of Kentucky.

2.2. Target cells
Equine tumor cell line, EqT8888 (Hormanski et al., 1992), was used as target cells in the
flow cytometric assay. The cells were cultured in RPMI-1640 (Gibco, Grand Island, NY)
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS, Gibco), 2 mM
glutamine (Sigma), and 100U/ml penicillin/streptomycin (Sigma) at 37 oC 5% CO2 in air.
Target cells were harvested in the log phase of growth before CFSE staining.

2.3. LAK cell generation
Heparinized blood was collected via aspetic venipuncture of the jugular vein. Peripheral
blood mononuclear cells (PBMC) were isolated using Ficol-Paque PlusTM (Amersham
Biosciences, Piscataway, NJ) gradient centrifugation according to the manufacturer’s
protocol. The PBMC were washed with phosphate-buffered saline (PBS) for three times
before re-suspending at 3X106 cells/ml in RPMI-1640 (Gibco, Grand Island, NY)
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supplemented with 2.5% (v/v) fetal equine serum (FES, Sigma, St.Louis, MO), 2mM
glutamine (Sigma), 100U/ml penicillin/streptomycin (Sigma), and 55 µM 2mercaptoethanol (GIBCO, Grand Island, NY). The PBMC were incubated up to 5 days in
T25 flasks supplemented with different concentration of recombinant human interleukin 2
(hIL-2; R&D Systems, Minneapolis, MN) to generate LAK cells (Hormanski et al., 1992).
All cultures were incubated at 37O C in 5% CO2 incubator. Each day, the LAK cells were
harvested and counted using a ViCell-XR instrument (Beckman Coulter, Miami, FL)
before use.

2.4. LAK cell flow cytometric assay
EqT8888 was re-suspended at 1.0 × 107 cells/ml in 1ml PBS followed by the addition of
1ml solution of 3 µM CFSE (Fluka BioChemika, Buchs, Switzerland). The solution was
gently mixed for exactly 8 min followed by the addition of 2ml of FBS to stop the reaction.
The target cells were washed three times with 10% (v/v) FBS in PBS and re-suspended at
a concentration of 3X105 cells/ ml prior to dispensing 100 µl of labeled cells into a 96 well
round bottom plate (Corning, Corning, NY). To each well of target cells was added a 100
µl volume of LAK cells at different cell concentrations to yield effector: target (E: T) ratios
of 40, 20, 10 and 5:1. Plates were then centrifuged at 200g for 5 min and incubated at 37oC
in 5% CO2 incubator. Samples with target cells only were used as spontaneous apoptosis
controls. To generate apoptosis positive control samples, EqT8888 cells were incubated
for 2 h in a 56oC water bath. Killing of the cells was confirmed by trypan blue staining.
All samples were performed in triplicate.
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After 3 h incubation, the cells were transferred to 96 well V bottom plates. The plates were
centrifuged at 300g for 5 min. Cells were washed by PBS for 2 times and re-suspended in
100 µl annexin V buffer (BD Pharmingen™), and transferred to 12 x 75mm tubes (BD
Pharmingen™). Annexin V (PE-conjugated, BD Pharmingen™) was added to each tube
and the cells were incubated in the dark at room temperature. After 15 min incubation, all
samples were acquired using a FACSCalibur and analyzed by CELL Quest Pro™ (Becton
Dickinson).

The target cells were gated using FL1 and 3000 gated events were acquired for each
sample. Target cells that underwent apoptosis were both CFSE (FL1) and Annexin V-PE
(FL2) positive. Each determination was performed in triplicate.

The percentage of

cytotoxicity was determined by the equation % cytotoxicity=
(%CFSE+Annexin V+ target in test well)-(%CFSE+Annexin V+ spontaneous release group)

x100
+

+

+

+

(%CFSE Annexin V total release group)-(%CFSE Annexin V spontaneous release group)

2.5. Relative quantitation of granzyme B, perforin and IFNγ gene expression by real-time
PCR
Approximately 3X106 LAK cells from each horse were collected and re-suspended in 1ml
RNA-STAT 60 (Tel-Test, Friendswood, TX) at the same time as the LAK cell flow
cytometric assay was performed. Total RNA was extracted using a phenol: chloroform
method (Chomczynski and Sacchi, 1987b). 1 µg RNA was dissolved in 41.5µl nucleasefree water (Qiagen, Valencia, CA) and transcribed into cDNA using 38.5µl reverse
transcription master mix (1 µl oligo dT primer [0.5 µg/ml; Promega], 4 µl dNTP [10mM;
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Promega], 0.5 µl avian myeloblastosis virus [AMV] reverse transcriptase [20U/ml;
Promega, Madison, WI], 16 µl AMV buffer [Promega], 1 µl RNAsin [40U/ul, Promega],
and 16 µl MgCl2 [25mM, Promega]), as previously described (Coombs et al., 2006). The
reactions were incubated at 42oC for 15 min and then 95 ℃ for 5min. The cDNA was stored
in -20oC until real-time PCR was performed.

Granzyme B, perforin and IFNγ (Coombs et al., 2006) gene expressions were determined
by real-time PCR (ABI systems 7900 Real-Time PCR Instrument, Foster City, CA). All
primer/probe sets were designed in intron-spanning region and failed to amplify genomic
DNA and reverse transcription negative RNA samples. The primer/probe sequences were
shown in Table 1. PCR reactions were incubated in duplicate wells for 95oC 10 min,
followed by 40 cycles of 95 oC for 15s and 60 ℃ for 60s. Each reaction contains 4.5 µl
cDNA and 5.5 µl master mix (0.5 µl 20X assay mix for primer/probe set of interest

[Applied Biosystems], and 5 µl TaqMan™ [Applied Biosystems, Foster City, CA]). Internal
PCR amplification efficiencies were calculated in LinReg PCR (Ramakers et al., 2003) to
confirm amplification efficiencies were above 99%. For relative quantitation, the △△C T
method (Livak and Schmittgen, 2001b) was used to determine changes in gene expression.

Beta-glucuronidase (β-GUS) was used as the housekeeping gene. The calibrator for each
target gene was calculated using the average of the medium control samples of each horse.
Relative quantity (RQ) was calculated as 2-△△CT (Livak and Schmittgen, 2001b).
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2.6. Statistical analysis
All data were analyzed for statistical significance using SigmaStat (Sigma Stat version 3.5;
Systat, San Jose, CA). One way analysis of variance (One way ANOVA) was used to
determine differences over time (1-5 days). Two way analysis of variance (Two way RM
ANOVA) was used to determine differences between separate age groups over time (1-5
days). Holm-Sidak method was used to identify differences in LAK activity and gene
expression over time and between horses of different ages. Statistical significance was set
at p<0.05. Correlations among granzyme B, perforin, IFNγ mRNA expression and flow
cytometric assay results were determined using the Pearson Product Moment Correlation.
Variables with positive correlation coefficient (r) and p values below 0.05 increased
together whereas variables with negative correlation coefficient (r) were inversely
correlated. There was no significant relationship when p>0.05.

3. Results
3.1. Target cell labeling with CFSE
One of the basic requirements for the flow cytometric determination of cytotoxicity is
stable labeling of target cells. Figure 1 shows the stability of the CFSE-labeled EqT8888
cells at 1 h, 2 h and 3 h after staining. The mean fluorescence of CFSE did not change over
the 3 h incubation period (data not shown).
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3.2 Demonstration of LAK cell activity
Equine PBMC were incubated with 200 units/ml recombinant hIL-2 for 96 h to generate
LAK cells. The LAK cells were added to labeled EqT8888 target cells to yield final
effector: target (E:T) ratios of 5, 10, 20 and 40. As the E: T ratio increased, the percentage
of CFSE+ Annexin V+ target cells also increased (Fig. 2a). Similar results were obtained
when five different horses were used as the source of PBMC to generate LAK activity,
though the overall cytotoxic activity for each individual horse was different (Fig. 2b).

3.3 Equine LAK activity is dependent on the doses of recombinant hIL-2
The generation of equine LAK activity is dependent upon the concentration of hIL-2 in the
culture (Hormanski et al., 1992). The PBMC from 5 horses were incubated with different
doses of recombinant hIL-2 for 96 h to generate LAK cells and assayed for the induction
of apoptosis in the EqT8888 cells (Fig. 3). The ability of the LAK cells to induce apoptosis
in the target cells was dependent on the doses of recombinant hIL-2 added to the LAK cell
cultures. The dose required for optimal killing was also dependent upon the horse tested.

3.4 Temporal induction of Equine LAK activity
PBMC were cultured with 2000 units/ml recombinant hIL-2 for 5 days. On each day, cells
were collected and tested for LAK activity using the flow cytometric assay for target cell
apoptosis. As shown in Figure 4a, LAK activity increased significantly with incubation
time (p<0.001) and optimal killing was obtained after 4 days incubation.
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3.5 Comparison of granzyme B, perforin and IFNγ mRNA expression with cytotoxic
activity in equine LAK cell cultures
Perforin, granzyme B and IFNγ have been used as surrogate markers for equine cytotoxic
cells (Issel et al., 1992; Paillot et al., 2005; Patton et al., 2005; Viveiros and Antczak, 1999).
Here, we determined mRNA expression of these markers in LAK cell cultures. PBMC
were collected from five horses and cultured with 2000 units/ml recombinant hIL-2 for 5
days, as above. Each day, cells were collected for real-time PCR analysis of mRNA
expression. Incubation with hIL-2 was associated with the increased expression of mRNA
for granzyme B, perforin and IFNγ though with different kinetics. Similar to LAK activity,
granzyme B mRNA expression increased with time (p=0.014). However, IFNγ mRNA
expression markedly increased only during the first day of culture (p<0.001) and decreased
significantly (p<0.001) thereafter. Perforin mRNA expression was induced by hIL-2
treatment, but remained fairly stable throughout the culture period (Figure 4a). When we
determined the relationship between gene expression and LAK activity, there was an only
significant positive correlation between EqT8888 apoptosis and granzyme B mRNA
expression (Figure 4b).

3.6 Reduced LAK activity in young horses is associated with decreased granzyme B
mRNA expression
PBMC from 1 year and 10 year old horses were cultured with 2000 units/ml human
recombinant IL-2 for 5 days for both flow cytometric assay and real-time PCR. As shown
in Figure 5, the 1-year-old horses’ LAK activity was significantly (p<0.001) lower than
the 10-year-old group over incubation time. This reduced cytotoxic activity was associated
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with significantly (p<0.001) lower expression of mRNA for granzyme B (Figure 5), but
not perforin or IFNγ (data not shown).
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Discussion
Cytotoxic cells play an important role in cell mediated immune responses against tumors
and intracellular pathogens. The most frequently used and widely accepted method for
determining cell-mediated cytotoxicity in vitro is the 51Cr release assay. While this assay
is sensitive and repeatable, it requires the use of radioactive materials and is timeconsuming to perform. Additionally, the 51Cr release assay cannot determine the ultimate
mechanism of cellular killing: cytolysis or apoptosis. There are two mechanisms whereby
cytotoxic cells induce apoptosis in their targets: granule exocytosis and Fas-FasL pathway.
Both NK and LAK cells have been shown to use the granule exocytosis pathway (Goldberg
et al., 1999; Henkart and Sitkovsky, 1994). In this pathway, granzyme B enters the target
cells via pores formed by perforin and cleaves procaspase-3 leading to the activation of the
caspase cascade (Derby et al., 2001). Once the caspases are activated, DNA fragmentation
and apoptosis occur (Henkart and Sitkovsky, 1994). Apoptosis is associated with the
translocation of phosphatidylserine from the inner side of the plasma membrane to the outer
layer which can be detected using annexin V (Vermes et al., 1995). We have previously
shown that incubation of equine PBMC with hIL-2 induces LAK activity, as measured by
51

Cr-release from EqT8888 cells (Hormanski et al., 1992). Here, we have utilized a non-

radioactive flow cytometric assay to identify phosphatidylserine residues on the plasma
membrane of the EqT8888 target cells following incubation with equine LAK cells. As
such, our results indicate that equine LAK cells induce target lysis via the induction of an
apoptotic pathway.
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Consistent with equine LAK cells using a granule-mediated pathway, we observed a
correlation between cytotoxic activity against EqT8888 cells and granzyme B mRNA
expression in the hIL-2 stimulated PBMC cultures. A similar relationship between human
LAK activity and granzyme expression has been reported (Lowrey et al., 1988). Perforin
mRNA expression was increased with IL-2 stimulation, though not correlated with
cytotoxic activity. Again, these results are consistent with previous reports on human
NK/LAK induction where perforin induction was induced by IL-2 stimulation, but not
necessarily correlated with cytotoxic activity (Clement et al., 1990). As both proteins exist
as preformed mediators in the granules of cytotoxic effector cells, it is perhaps not
surprising that there was not a better correlation between their expression and absolute
cytotoxic activity. This also likely reflects the multiple steps involved in cytotoxic activity
including recognition and binding of the target cells, formation of the synapse, lysis of
target cells, and recycling of the effector cells.

In addition to their cytotoxic activity, LAK cells also secrete inflammatory cytokines such
as IFNγ(Choi et al., 2008). Here, too, we detected increased expression of this cytokine
post-IL-2 stimulation. In contrast to the other markers, IFNγ expression peaked early in
the culture period and was thus inversely correlated with LAK activity in the culture over
time. While IFNγ has frequently been used as surrogate marker for cytotoxic cell activity
in equine research (Breathnach et al., 2005; Ellis et al., 1997; Paillot et al., 2006), this lack
of correlation with cytotoxic activity and the fact that other non-cytotoxic cells produce
this cytokine, makes it a poor choice as a surrogate marker for LAK cells.
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While several studies of human LAK activity have shown similar levels of cytotoxicty in
PBMC cultures from young children compared to adults (Ayello et al., 2009; Montagna et
al., 1988), we observed a significant difference in cytotoxicity and granzyme B gene
expression between the young and older horses used in this study. While the reasons for
this age-dependent difference in the horse are unknown, one possible explanation could be
the sources of the LAK activity. Human LAK activity is associated with both activated
NK cells as well as CD8+ TcR+ cells (Mingari et al., 1987; Provinciali et al., 1995), these
latter cells likely representing CTL. In the horse, LAK activity is similarly associated with
a population of CD3+ CD8+ cells (Lunn et al., 1996; Viveiros and Antczak, 1999) and
equine NK cells do not exhibit cytotoxic activity against the EqT8888 cell line (Viveiros
and Antczak, 1999). Younger horses likely have a lower frequency of CTLs in their
peripheral blood compared to adults which could account for their reduced LAK activity.

In summary, we have utilized a flow cytometric assay to demonstrate equine LAK cell
activity. In addition to providing several advantages in terms of safety and cost, this
approach allowed for the identification of apoptosis as the likely killing mechanism. RTPCR analysis of IL-2 stimulated gene expression in LAK cell cultures provided additional
supporting evidence for a granule-mediated cytotoxicity involving perforin and granzyme
B, but not IFNγ. We were also able to determine that the reduced LAK activity in young
horses was associated with decreased expression of granzyme B mRNA, likely reflecting
fewer LAK precursor cells in their circulation.
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Table 1. Primer/probe sets used for gene expression measurements
Amplicon
length
(bp)

Gene

Sequence
(5'-3')

β-GUS

Forward

GCTCATCTGGAACTTTGCTGATTTT

Reverse

CTGACGAGTGAAGATCCCCTTT

Probe

CTCTCTGCGGTGACTGG

Forward

AGCAGCACCAGCAAGCT

Reverse

TTTGCGCTGGACCTTCAGA

Probe

ATTCAGATTCCGGTAAATGA

Forward

GGACCCGAAGGAAAAGAAGTCTT

Reverse

CCTGGATCACGTTCTTACACACAAG

Probe

CCGGAGTCCCCCTTAAA

Forward

GCTTCAGCAGCGACTCAGT

Reverse

CGTGCACCAGGCGAAA

Probe

ACTGTAGAAGCGACACTCC

IFNγ

Granzyme B

Perforin

85

75

74

54

β-GUS=beta-glucuronidase; Probe: dual-labeled oligonucleotide with 5-FAM and 3NFQ;
β-GUS, IFNγ (Coombs et al., 2006).
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Figure 1. EqT8888 cells exhibit stable labeling with CFSE. 1.5µM CFSE was added to
7X106 EqT8888 cells. After 1h, 2h and 3h incubation, EqT8888 cells were acquired and
analyzed using flow cytometry. Data is representative of multiple experiments.
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Figure 2 Flow cytometirc detection of equine LAK activity. (a) Apoptosis induction in
EqT8888 cells by equine LAK cells. 30,000 target cells were cultured for 3 h in 5% CO2
with different number of LAK cells yielding E: T ratio from 5, 10, 20 to 40. Data from
(A06) is shown. (b) LAK cell activity of multiple horses. While the percentage of
apoptotic target cells increased as the E:T ratios increased in all cases, overall LAK activity
was different among the measured. All determinations were performed in triplicate.
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Figure 3. Dose-dependent induction of equine LAK activity by recombinant hIL-2. LAK
cells were generated using 20, 200 and 2000 units/ml recombinant hIL-2. After 96h, LAK
cells were co-cultured with EqT8888 cells at E: T ratio 10 for 3h. Flow cytometric assay
was used to determine apoptosis. All determinations were performed in triplicate.
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Figure 4. Comparison of LAK activity and gene expressions. (a) Temporal induction of
LAK activity and mRNA expression in PBMC cultures. PBMC were incubated with 2000
U hIL-2 for various times for both flow cytometric assay of LAK activity and real-time
PCR analysis of gene expression, as indicated.

Flow cytometric determination of

cytotoxicity was performed in triplicate. Means without a common letters (a,b,c) differ at
p<0.05. (b) Granzyme B mRNA expression correlates with LAK activity. Relationships
between LAK activity and granzyme B mRNA expression were assessed by Pearson
Product Moment Correlation. Linear regression line, correlation coefficient (r), and p value
is shown.
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Figure 5. Younger horses exhibit reduced LAK activity and granzyme B mRNA
expression. PBMC from 1 and 10 year old horses were cultured with 2000 units/ml human
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recombinant IL-2 for 5 days. LAK activity, determined by flow cytometric assay on the
days indicated. Granzyme B, perforin and IFNγ mRNA expression was determined by
real-time PCR daily. Two-way RM-ANOVA was used to identify differences between age
groups over time. The Holm-Sidak method was used to determine differences between age
groups at each day. An * indicates significant difference at p<0.05.
Copyright © Chong Liu 2013
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